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ABSTRACT 
STRATEGIES FOR ENHANCING THE ANALYTICAL PEFORMANCE 
 AND BIOCOMPATBILITY OF INTRAVASCULAR 
AMPEROMETRIC GLUCOSE SENSORS 
by 
Alexander K. Wolf 
 
Chair: Dr. Mark E. Meyerhoff 
Ensuring accurate analytical performance that can overcome the body’s response to foreign 
objects is an integral part of developing improved in vivo biosensors.  Blood contact from 
intravenous placement of such sensors readily results in surface clot formation, and blood-born 
electroactive species obscure the desired signal response.  In this thesis, improvements of 
amperometric glucose sensor selectivity are combined with strategies to augment surface 
hemocompatibility with the aim of enhancing the in vivo analytical performance of such devices.   
Annealing thin films and membranes of the sulfonated fluoropolymer Nafion causes 
morphological changes to the hydrophilic regions, altering their transport properties.  Addition of 
a novel annealed Nafion layer to the electrode cavity of needle/catheter-type glucose sensors is 
shown to enhance selectivity over ascorbic and uric acid (<3 % of signal response for 5 mM 
glucose at typical levels of ascorbic and uric acid in blood) for a duration of at least 8 days. 
The transmembrane CD47 protein is ubiquitously expressed in many cells as a marker of 
“self”.  A temporary “handshake” interaction with its cognate receptor on inflammatory response 
xix 
 
cells (SIRPα) suppresses platelet activation.  Herein, the outer polyurethane coatings of glucose 
sensors were functionalized with 85.0 ng/cm2 of recombinant human CD47.  In vitro calibrations 
confirm that immobilization has no adverse impact on the sensors’ glucose response properties or 
selectivity against interference species.   
Nitric oxide (NO) is a potent antithrombotic molecule, endogenously released by endothelial 
cells to prevent platelet activation and clot formation.  Polymer layers of poly(lactic acid) 
containing the NO donor molecule diazeniumdiolated N,N’-dibutyl-1,6-hexanediamine 
(DBHD/N2O2) grant surface thromboresistance to glucose sensor surfaces by mimicking 
endogenous NO release from endothelial cells at a localized flux >0.5×10-10 mol cm-2 min-1 for at 
least 7 d.  Intravascular amperometric glucose sensors prepared with such NO release coatings 
accurately trace modulations of in vivo glucose concentration within rabbit veins for 7 h.  
Preliminary in vivo glucose measurements for 20 h porcine veins are also examined and extensive 
in vitro investigations are conducted to identify sources of significant sensor calibration drift 
observed in the porcine model. 
Finally, the Edwards GlucoClear, a commercial intermittent glucose sensing system, is 
configured for transient NO release.  Preliminary data and diffusion modeling suggest that a source 
silicone rubber catheter sensor housing can be loaded with S-nitroso-N-acetylpenicillamine 
(SNAP), an NO releasing donor.  NO released from the catheter partitions uniformly into the thin 
outer polyurethane sensor coating at a projected concentration of 6.77 x 10-5 M during a 5 min 
charging phase, enabling transient NO release above >0.5×10-10 mol cm-2 min-1 for a significant 
period (>5 min) after the sensor removal from the NO source, simulating in vivo blood contact.  
Rapid glucose response time and linearity of the sensors are preserved. 
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CHAPTER 1 
CURRENT STATUS OF IN VIVO SENSORS FOR CONTINUOUS MONITORING OF 
CRITICAL CARE ANALYTES: BIOCOMPATIBILITY CHALLENGES AND 
POTENTIAL SOLUTIONS* 
1.1 Introduction 
Advances in electrochemical and optical sensors designed for specific ions (H+, Na+, K+, 
Ca+2, Cl-), gases (PO2, PCO2), and low molecular weight biomolecules (e.g., glucose, 
lactate, creatinine, urea, etc.) over the past 40 years have revolutionized the measurement of 
such species in the clinical setting, enabling rapid, near patient/point-of-care testing of such 
critical care analytes in undiluted blood samples.
1,2  However, nearly all existing sensor-based 
measurement systems require discrete samples of blood.  Only a few commercial systems are 
designed for continuous monitoring capability either in vivo (for glucose monitoring in 
subcutaneous fluid
3,4
) or for short periods in blood within the bypass blood loops used during 
open-heart surgery (where blood clotting is prevented with high levels of anticoagulant).
5,6   
*Note: This chapter is adapted from the following book chapter that was coauthored by this Ph.D. 
candidate: M. C. Frost, A. K Wolf, and M.E. Meyerhoff, “In Vivo Sensors for Continuous 
Monitoring of Blood Gases, Glucose and Lactate,” RSC Detection Science Series No. 2 Detection 
Challenges in Clinical Diagnostics, P. Vadgama and S. Peteu  (Editors); The Royal Society of 
Chemistry, 2013. 
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Even the existing implantable sensors for glucose that are commercially available have significant 
limitations in their accuracy, requiring frequent calibration and confirmation of results via separate 
in vitro measurements of blood glucose using conventional glucometer test strips.
7–10
 
Although there have been enormous efforts over the past 25 years by many companies to 
develop catheter-type sensors that could monitor blood gases (oxygen, carbon dioxide and 
pH) within arteries of critically ill patients using miniaturized electrochemical or optical 
sensors,
11–14 all of these efforts failed to produce a successful product.  The lack of success in 
developing implantable chemical sensors that can provide reliable analytical results, especially 
for the blood gas test panel (PO2, PCO2, and pH), as well as for glucose and lactate (note: 
lactate levels are a major indicator of status for intensive-care patients
15–17
) can be attributed 
primarily to the biological response to the indwelling sensors. 
In this chapter, the status of implantable chemical sensor technology for these analytes 
are reviewed.  In addition, the fundamental biocompatibility problems inherent to both 
intravascular (placed in the blood stream) and subcutaneous (implanted under the skin) chemical 
sensors and new approaches aimed at solving these fundamental problems that might enable 
greatly enhanced analytical performance for indwelling chemical sensing devices are summarized. 
 
1.2 Design of In Vivo Sensors 
The basic requirements for sensors potentially useful for continuous real-time, in vivo 
measurements are: a) be of very small size (< 1 mm o.d.) for easy placement within a blood 
vessel (i.e., artery for blood gases/pH; vein for glucose/lactate) or under the skin in 
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subcutaneous space (primarily for glucose); b) exhibit long-term analytical signal stability 
(limiting frequency of recalibration); c) cannot exude toxic chemicals into the patient; and d) 
provide reliable analyte values that correlate with conventional in vitro tests that use discrete 
blood samples, ideally such that analyte values reported by the implanted sensor can be used 
in place of discrete blood-test measurements to initiate appropriate medical therapy. 
1.2.1 Sensing PO2/PCO2/pH in Blood 
Miniaturized versions of both electrochemical (potentiometric and amperometric) and 
optical sensors have been employed to prepare intravascular devices.  Figure 1.1 for illustrates 
the overall concept of intravascular blood-gas/pH sensors to monitor patients continuously.  
Optical sensors have certain advantages over electrochemical devices, including (1) ease of 
miniaturization using modern optical fibers; (2) potentially less electronic noise (no 
transduction wires); (3) potential long-term stability using ratiometric measurements at multiple 
wavelengths; and (4) no need for a separate reference electrode.  These advantages promoted the 
development of optical sensor technology initially for the design of intravascular blood gas 
sensors using multiple optical fibers.
11  
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Figure 1.1. Overall concept of in vivo blood gas/pH patient monitoring system based on use 
of intravascular chemical sensors. Sensor inserted in to artery would be able to continuously 
monitor oxygen, carbon dioxide, and pH levels in arterial blood. 
 
  
 
Figure 1.2. Schematic of intravascular optical blood-gas/pH sensing catheter configuration that 
uses three optical fibers to carry light to and from fluorescent dyes in sensing layers that 
enables optical detection of pH, PCO2, and PO2. This configuration is based on US Patent # 
5,047,627 (1991). 
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In such systems, light is passed to and from the sensing site that contains immobilized dyes 
sensitive to the analyte species by the optical fibers and measures (by reflectance) the fluorescence 
or phosphorescence originating from the immobilized indicator at the distal end of the fibers (see 
Figure 1.2 for multifiber design for intravascular blood gas/pH sensing originally patented by 
Abbott Laboratories).  Optical fiber sensors for PO2 measurements are typically based on the 
immobilization of certain organic dyes, such as pyrene, diphenylphe- nanthrene, phenanthrene, 
fluoranthene, or metal ligand complexes, such as ruthenium[II] tris[dipyridine], or Pt and Pd 
metalloporphyrins within hydrophobic polymer films (e.g., silicone rubber) in which oxygen is 
very soluble.
18,19  The fluorescence or phosphorescence of such species at a given wavelength is 
often quenched in the presence of paramagnetic species, including molecular oxygen. In the case 
of embedded fluorescent dyes, the intensity of the emitted fluorescence of such films will decrease 
in proportion to the PO2 of the sample in contact with the polymer film.  Optical-fiber oxygen 
sensors have also been developed using a luminophore platinum (II) mesotetrakis(penta- 
fluorophenyl)porphyrin (PtTFPP) complex embedded in different sol-gels.
20,21  The fluorescence 
of the PtTFPP is quenched in the presence of oxygen.   
Optical sensors suitable for the determination of PCO2 employ optical pH transducers 
(with immobilized indicators) as inner transducers in an arrangement quite similar to the classic 
Stow–Severinghaus style electrochemical PCO2 sensor design.  In this design, the pH-sensing 
layer is behind an outer gas permeable coating (e.g., silicone rubber) that prevents sample 
proton access to the pH sensing layer (see Figure 1.3).
22
 The addition of bicarbonate salt within 
the pH-sensing hydrogel layer creates the required electrolyte film layer, which varies in pH 
depending on the partial pressure of PCO2 in equilibrium with the film.  As the partial pressure 
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of PCO2 in the sample increases, the pH of the bicarbonate layer decreases, and the 
corresponding decrease in the concentration of the deprotonated form of the indicator (or 
increase in the concentration of protonated form) is optically sensed.  An alternate optical 
intravascular PCO2 sensor was developed by Jin, et al.
23 using the fluorescence indicator 1-
hydroxypyrene-3,6,8-trisulfonate that directly interacts with CO2. 
Optical pH sensors require immobilization of appropriate pH indicators within thin layers 
of hydrophilic polymers (e.g., hydrogels) because equilibrium access of protons to the indicator 
is essential.  Fluorescein or 8-hydroxy-1,2,6-pyrene trisulfonate (HPTS) have often been used 
as the indicators and the fluorescence of the protonated or deprotonated form of the dyes can be 
used for sensing purposes.
24   
Jin and coworkers report the fabrication of an intra-arterial pH sensor based on fluorescence 
using N-allyl-4-piperazinyl-1,8-napthalimide and 2-hydroxyethyl methacrylate.
25  The sensors 
were tested in rabbits and showed appropriate response times (t90 ¼ 13.7 ± 0.8 s to 109.61 ± 
4.06 s, depending on the conditions of the pH change) that are quite useful for real-time 
monitoring.  One problem with respect to using immobilized indicators for accurate 
physiological pH measurements is the effect of ionic strength on the pKa of the indicator.
26 
Because optical sensors measure the concentration of protonated or deprotonated dye as an 
indirect measure of hydrogen ion activity, variations in the ionic strength of the physiological 
sample have been known to influence the accuracy of the pH measurement.   
While many of the prototypes for implantable blood gas monitoring developed in the 
1980s/1990s were based on optical sensors that could be easily inserted in the radial artery of 
patients, miniaturized electrochemical sensors have also been described for in vivo sensing of 
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blood gases.
11–13  Electrochemical oxygen sensing catheters are based on the Clark-style 
oxygen sensing configuration (Figure 1.4), in which a platinum wire along with a Ag/AgCl 
or other reference electrode are placed within a narrow gas permeable tubing filled with an 
electrolyte solution.
11
 
 
 
 
Figure 1.3. Basic in vivo PCO2 sensing configuration that can be employed to detect carbon 
dioxide levels in blood using inner electrochemical or optical pH sensor. 
 
 
 
 
Figure 1.4. General design of implantable electrochemical PO2 sensing catheter, where 
oxygen in sample permeates outer tubing wall of the catheter and is reduced electrochemically 
at working Pt wire electrode. The current flow is directly proportional to the PO2 level in the 
blood stream. 
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For the electrochemical oxygen sensing catheters, oxygen within the blood stream diffuses 
through the walls of the tubing and is reduced electrochemically at the Pt working electrode 
via application of a – 0.6 to – 0.7 V vs. the Ag/AgCl reference electrode. The resulting current 
in the circuit is proportional to the PO2 levels in the blood. 
Electrochemical PCO2 sensors suitable for intravascular sensing are typically prepared with 
miniature pH sensors, ideally non-glass potentiometric devices, made with metal oxides
27 or 
ionophore-based polymer membrane devices
28,29 
that contain modified filling solutions.  
Carbon dioxide diffusion through the walls of a catheter tubing changes the pH within an 
inner bicarbonate filling solution.  In one proposed in vivo sensor configuration, the pH 
ionophore tridodecylamine was impregnated into the walls of a dual lumen silicone rubber 
catheter tubing, with one of the lumens filled with buffer and the other with bicarbonate 
solution.  The voltage between Ag/AgCl electrodes placed in each lumen is dependent on the 
PCO2 level in the sample surrounding the tubing, since the wall between the two lumens is pH 
sensitive and detects the pH change within the lumen filled with the bicarbonate solution.  If an 
external reference electrode is also employed, then the voltage between the Ag/AgCl wire in 
the buffered lumen vs. the external reference is related to the pH of the sample phase.  Other 
recent work focused on electrochemical pH sensing includes a report by Makos, et al.
30 who 
developed a modified carbon-fiber electrode by the reduction of the diazonium salt Fast Blue 
RR on the fiber.  The resultant sensor was capable of monitoring pH changes as small as 0.005 
pH units.  Huang and coworkers
31 report the fabrication of a flexible pH sensor utilizing a 
polymer substrate with an iridium oxide sensing layer, a sol-gel matrix, and an electroplated 
AgCl reference electrode.  The ability to conform to a variety of shapes offers a wide range 
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of potential applications. 
 
1.2.2 Sensing Glucose in Subcutaneous Tissue 
The vast majority of sensors that can be implanted subcutaneously for continuous glucose 
monitoring (CGM) and lactate monitoring are electrochemical devices.
7,32–40  For glucose 
sensors, the enzyme glucose oxidase is most often employed as an immobilized catalyst on the 
surface of a suitable electrochemical transducer.   Some configurations use amperometric oxygen 
sensors with glucose oxidase immobilized as layer on the outer surface.  Glucose present in the 
bathing solution at the sensor reacts with oxygen via the enzyme, lowering the partial pressure 
of oxygen immediately adjacent to the outer gas-permeable membrane of the oxygen sensor.  
The decrease in PO2 and concomitant current decrease is proportional to the level of glucose in 
the surrounding blood or tissue.  However, typically, a second non-enzyme covered PO2 sensor 
is required to monitor the level of PO2 present in the sample phase.  Similar configurations 
based on optical PO2 sensors have also been reported.
41
 
More often, implantable glucose sensors are fabricated using electrochemical oxidation of 
hydrogen peroxide (H2O2), produced by the immobilized glucose oxidase catalyzed reaction 
of glucose and oxygen.  This is normally accomplished using a small surface area of platinum 
wire as the anode and an applied voltage of +0.6 to +0.7 V vs. an external Ag/AgCl electrode.  
Other physiological species (e.g., ascorbic acid, uric acid, etc.) can be oxidized at this potential, 
so additional layers of membranes/coatings that decrease access of these species to the platinum 
surface are required.  Specifically, the use of annealed Nafion membranes on implantable 
glucose sensors to select against these species is highlighted in Chapter 2 of this thesis.  Further, 
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the outermost layer of such sensors requires a polymeric coating (illustrated in Figure 1.5) 
that restricts glucose diffusion
42 so that the glucose concentrations within the underlying 
immobilized enzyme layer are always less than the lowest levels of oxygen that might be present 
in the in vivo sample phase.  This requirement greatly decreases the sensitivity of the devices 
to variations in localized oxygen levels and also enables the sensors to respond linearly to 
abnormally high levels of glucose (up to 20 mM) that might be present in blood or tissue of 
diabetic patients. 
Another approach taken to prepare in vivo glucose sensors uses immobilized redox hydrogels 
in which tethered mediator sites (e.g., ferrocene or Os(III) redox species) are able to accept 
electrons from the reduced form of the immobilized glucose oxidase enzyme after reaction 
with glucose.
43  These reduced mediators are then oxidized and hence the steady-state current is 
directly proportional to glucose concentration.  The advantage of the mediator-based devices 
is that they partially reduce the need for outer membranes that carefully control the flux of glucose 
relative to oxygen.  Further, the applied potential to the inner conductive electrode material 
can be less positive to reoxidize the mediator (compared to hydrogen peroxide), reducing the 
need for exclusion layers to block potential oxidizable species present in the in vivo milieu. 
There have been a few optical-based glucose sensors reported with small size required for 
implantation.
44  These are usually fluorescent sensors that utilize glucose-binding proteins and 
fluorophore-labeled saccharides in a competitive binding mode behind membranes that are 
permeable to glucose. 
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Figure 1.5.  One design of subcutaneous or intravascular glucose sensors (diameter <0.6 mm), 
with glucose oxidase (GOx) immobilized over surface of Pt/Ir wire and a coiled Ag/AgCl 
reference electrode.  The outer polyurethane layer decreases the rate of glucose access to enzyme 
layer, while allowing rapid diffusion of oxygen, that enables the sensor to exhibit a linear 
response to high levels of glucose (to 20 mM). The Pt/Ir electrode is poised at +0.65 V vs. 
Ag/AgCl to oxidize hydrogen peroxide generated from the enzymatic reaction. 
(With permission from reference 11.) 
 
Recent developments in electrochemical glucose sensors have branched in several 
directions from the second-generation sensors described above.  Some continue to utilize the 
glucose oxidase/hydrogen peroxide enzyme electrodes, but they feature novel outer layers to 
limit glucose diffusion to extend the linear range and to extend the stability and lifetime of 
the sensors.  Others have worked to eliminate electron-transfer mediators through the use 
of carbon nanotubes.  Amperometric glucose sensors developed by Tipnis et al.
45 follow the 
standard design of immobilized glucose oxidase to generate hydrogen peroxide for oxidation.  
Glucose concentration is still determined from the measured steady-state current, but these 
sensors incorporate a layer-by-layer (LBL) assembled film as an outer coat to both limit 
glucose diffusion and minimize calcification, which can clog sensor pores or crack the outer 
membrane.  LBL coatings of humic acids (HAs) and ferric chloride (FeCl3) of various 
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thicknesses were compared to optimize the number of layers to tune glucose diffusion from 
the bulk to the sensor surface.
45  Lin et al. constructed sensors that utilized low density carbon 
nanotubes (CNT) for direct electron transfer between the enzyme and the electrode surface so 
that sensors neither required an electron mediator nor an outer glucose limiting layer.
46,47  
These sensors had a large linear range (2–30 mM).  Even more promising are sensors fabricated 
with carbon nanotube fibers, spun into nanoyarns.
48  The fibers are unwound at the tip to 
create a ‘‘brush’’ onto which glucose oxidase is immobilized and an outer polyurethane outer 
membrane is applied.  These sensors exhibit limits of detection as low as 25 mM, although 
such low detection levels are not required for blood glucose measurements.  Using nickel or 
copper nanoparticles to make a CNT array also lowered the limit of detection.
48
 
Recent glucose sensors have also once again utilized optical detection to take advantage 
of technological developments in optical materials and the high degree of reversibility 
characteristic of optical sensors.  Tierney et al. fabricated glucose sensors that function by 
covalent binding of an acrylamide-based hydrogel to the tip of an optical fiber.
49  The local 
glucose concentration swelled and contracted the phenylboronic acid within the hydrogel, 
changing the optical path length, which was measured by the optical fiber.  What especially sets 
these optical sensors apart is their elimination of the need for a fluorescent molecule or tag.  
The sensors had high reversibility but could have interferences from glycoproteins, 
polysaccharides, elevated blood levels of lactate, and the common anticoagulants heparin and 
citrate.  Sensor function was also significantly temperature dependent, as the difference between 
room and body temperature significantly affected the equilibrium swelling degree.  Glucose 
sensors developed by Paek et al. utilize a reversible glucose binder, rather than a catalytic 
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enzyme reaction that consumes local glucose and optical detection, that would not suffer signal 
noise electromagnetic fields, and could use a detector that was spatially separated from the 
sensor.
50  The sensor functioned by competitive binding between glucose and a ligand 
conjugate for the immobilized glucose-selective protein (concanavalin A), which caused a 
detectable wavelength shift in the optical sensor.   However, in order or preserve sensor lifetime 
for CGM and recycle the ligand conjugate, the sensing area must be separated from the sample 
by a semipermeable membrane selective for glucose diffusion.  All of these sensors show 
promise in helping to extend the linear working range of glucose sensors and replace the sensitive 
glucose oxidase enzyme; however, the biocompatibility of these sensors to thrombosis and 
immune response from long-term in vivo implantation has yet to be assessed. 
Despite tremendous advances in sensor design, however, none of these designs have yet 
achieved widespread use, and all existing commercial in vivo glucose sensors are either 
based on electrochemical detection of hydrogen peroxide or redox-mediator species.  Indeed, 
Table 1.1 lists the current commercially available electrochemical glucose sensors, the lifetime 
of the sensor in vivo, and the suggested frequency of recalibration.  The only FDA approved 
devices (by Medtronic-Minimed, Abbott Inc., Dexcom Inc.) require recalibration in vivo several 
hours after implantation (via repeated in vitro blood tests by the diabetic patient).
7–10  Even with 
such measures, the outputs of the devices are still not reliable enough for the patient to 
exclusively use values for monitoring glucose levels to decide on insulin doses.   
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Table 1.1.  The current commercially available in vivo (all subcutaneous) electrochemical 
glucose sensors, sensor lifetime, and the suggested frequency of recalibration. 
 
 
1.2.3 Sensing Lactate in Blood 
As mentioned above, continuous lactate measurements would be most useful in intensive-
care units within hospitals since elevated lactate levels in blood are a negative predictor of a 
good outcome for such patients.  Indeed, many critical-care doctors believe that trends in 
blood-lactate levels provide the best indicator of tissue oxygenation in patients, and when lactate 
levels continue to rise, therapy is failing, and patient survival rate is greatly decreased.
15–17  
Hence, an intravenous catheter that could provide reliable real-time lactate concentrations 
would be highly desirable.  Several indwelling lactate sensors have been reported,
51,52 and 
most are based on a design quite similar to the aforementioned glucose sensors,  except that 
lactate oxidase is used as the immobilized enzyme.  The enzyme produces hydrogen peroxide, 
and thus oxidation of this product species at a platinum, or other electrode material, provides 
the transduction method.  Since levels of lactate are generally lower than glucose, controlling 
fluxes of lactate into the immobilized enzyme, relative to oxygen, is not quite as stringent, 
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although still important.  
Recent developments in lactate sensors have also utilized both electrochemical and optical 
detection methods.  While glucose sensor development has largely focused on applications for 
in vivo continuous monitoring for diabetic patients and patients under tight glycemic control, 
several recent lactate sensors have been designed for in vitro measurements of cell cultures, as 
increased lactate production has been identified as a cancer marker.  A potentiometric sensor 
based on zinc-oxide nanorods was developed recently by Ibupoto et al.  The ZnO nanorods 
were grown on gold-coated glass and lactate oxidase was subsequently immobilized on the 
surface.
53  The sensors showed excellent linear response range, stability for more than three 
weeks, and high selectivity over potential interfering species such as ascorbic acid, urea, 
glucose, galactose, and Mg
2+ and Ca
2+ ions.  However, the sensor’s response decreased at 
pH >8 and with temperatures above room temperature, necessitating a stable operating pH 
and temperature for the accurate and consistent measurements needed for a continuous 
monitoring system. 
Zheng, et al. developed an optical-fiber nanosensor based on lactate dehydrogenase capable 
of measuring extracellular lactate concentration at the single-cell level.  Lactate dehydrogenase 
immobilized at the tip of an aluminum-coated, heated/pulled optical fiber generates NADH as 
a fluorescent byproduct, directly proportional to the local lactate concentration.  When excited 
by 360-nm UV light, the NADH fluoresces at 460 nm, allowing extremely sensitive and 
selective detection.  While this promises to be an excellent technique for identifying cancerous 
cells in vitro, no plans have been made to use the sensors for implanted in vivo measurements.
54  
Another very recent lactate sensor designed by Martín et al. utilizes genetically encoded Förster 
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resonance energy transfer (FRET) and fluorescence-based detection to measure local lactate 
extracellular concentration.
55  The sensor design proved extremely selective and very sensitive 
(single cell), but was pH sensitive and difficult to fabricate.  Future in vivo lactate sensors, 
designed for continuous monitoring of patients to indicate health of critically ill patients may 
still utilize electrochemical detection, but could also benefit from the methods designed to 
improve the biocompatibility of implanted in vivo glucose measurements. 
 
1.3 Biocompatibility Issues that Influence In Vivo Sensor Performance and Reliability 
Several research teams actually fabricated prototype blood-gas/pH-sensing catheter 
products that were evaluated first in animals and then in humans.
13,56–59  Despite claims of 
success by some investigators, significant problems remain.  A common observation for some 
sensors during in vivo studies is the performance pattern illustrated in Figure 1.6.  Specifically, 
after a given period of time, sensor output signals often begin to deviate significantly from the 
values obtained for discrete blood samples analyzed in vitro on conventional laboratory 
instruments.  The pattern is always the same, with intravascular sensor values for pH and PO2 
always lower than corresponding in vitro measurements and PCO2 levels always higher than 
the corresponding in vitro values.  This behavior was initially thought to arise exclusively from 
thrombus formation on the surface of implanted sensors, in which platelets and other 
entrapped metabolically active cells create a local environment that differs in PO2, PCO2 and 
pH levels compared to the bulk blood (due to cellular respiration).  Although this effect will 
certainly be accentuated by the formation of a thick thrombus layer, even the adhesion of a 
single layer of metabolically active cells, e.g. platelets, could cause a local change in analyte 
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concentrations immediately adjacent to the surface of the device.  Similar errors can be observed 
for glucose measurements, given the ability of cells to metabolize glucose, creating lower 
values near the surface of cell coated sensors. 
 
 
 
Figure 1.6.  Overall concept of in vivo blood gas/pH patient monitoring system based on use 
of intravascular chemical sensors. Sensor inserted in to artery would be able to continuously 
monitor oxygen, carbon dioxide and pH levels in the atrial blood. 
 
1.3.1 Details of Biological Response in Blood 
Platelet adhesion and activation on foreign surfaces, such as the outer coatings of 
intravascular sensors, is primarily governed by the ability of platelets to recognize certain 
proteins that adsorb on the device surfaces once they are inserted into the bloodstream.  Two 
proteins, von Willebrand’s Factor (vWF) and fibrinogen, play key roles in this process.60  
vWF is a circulating protein that readily adsorbs to collagen and foreign materials that do not 
an have intact endothelial layer.  Upon adsorption, vWF will bind with glycoprotein Ib (GPIb) 
on the surface of platelets to form the GPIb-V-IX complex, which allows platelet adhesion to 
the device surface.61  Adherent and activated platelets release a host of factors that promote 
more platelet adhesion and accelerate the coagulation cascade including prostaglandins 
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(PGH2 and PGG2), Ca
2+, and thromboxane A2.
62  Thomboxane A2 promotes the 
presentation of GP IIb/IIIa on the surface of platelets that actively binds circulating 
fibrinogen, linking platelets together and locally converting fibrinogen to insoluble fibrin.
62  
Fibrin entangles blood cells and forms the physical barrier that covers devices placed in blood.  
In addition to the role of platelets in coagulation, coagulation factor XII and platelet factor 3 
(which is released by adherent platelets) will bind directly to the foreign surface and also 
convert prothrombin to thrombin, which will further promote the conversion of fibrinogen to 
fibrin (see Figure 1.7).
62  As mentioned above, even if significant blood clots are not formed, the 
presence of just a single layer of active platelets and other potential cells can alter the 
analyte concentrations near the surface of the implanted sensor, yielding inaccurate values 
compared to the concentration measured in the bulk blood phase. Within the realm of 
designing intravascular sensors, it is critical to be aware that the dynamic nature of this surface 
interaction is a significant challenge to obtaining accurate measurements of physiologically 
important analytes. 
 
 
Figure 1.7.  Physiological response to the outer surface of a sensor placed into the blood 
stream, ultimately causing activation of platelets and potentially thrombus formation on all 
or part of the sensor’s surface.  The coatings of cells on sensor surface can cause significant 
errors in the measurement of the target analytes. 
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1.3.2 Details of Biological Response in Subcutaneous Tissue 
Sensors developed for real-time subcutaneous measurements, most notably 
electrochemical glucose sensors,
12–21 do not suffer from accuracy issues related to platelet 
activation and thrombus  formation.  However, such sensors are subject to their own unique 
biocompatibility problems that can influence the analytical performance of the implanted 
devices.
63,64  Specifically, a significant tissue inflammatory response to a large ‘‘foreign body’’ 
(i.e., the sensor) can lead to encapsulation of the devices within a sheath of leukocytes, 
macrophages, and fibroblasts (see Figure 1.8).  This sheath can alter local analyte levels 
(e.g., glucose) via metabolic reactions (e.g., inflamed tissues consume glucose at an 
accelerated rate
12,32,65,66
) and also greatly perturb mass transfer of the analyte to the sensor surface 
as well as between the blood and the interstitial fluid region.  Such changes can effectively alter 
the calibration curve (e.g., change sensitivity) for the device and can also greatly affect the lag 
time of the sensors response to varying glucose levels in the bulk blood.
12,32,67
 
When foreign materials are placed in subcutaneous tissue, the inflammatory response poses 
significant challenges to stable sensor performance.  Upon implantation of a sensor, an acute 
response occurs that lasts from minutes up to days.
68  As is the case with intravascular sensors, 
nearly instantly, proteins adsorb to the surface of the device.  Due to the need to pass through 
vascularized tissue to place the sensors in subcutaneous tissue, both plasma and tissue 
proteins such as albumin, fibrinogen, complement factors, globulins, fibronectin, and 
vitronectin adsorb to the device.
68  Mast cells (MCs) present in subcutaneous tissue play a 
central role in regulating inflammation.
69,70
  Upon injury, MCs will release a series of stored 
proinflammatory agents including vasoactive amine, chemotactic factors and proteases.  As a 
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result of sustained stimulation, they will then synthesize and continue to release pro-
inflammatory mediators that will recruit macrophages and lymphocytes.  Additionally, they 
release vascular endothelial cell growth factor (VEGF) that is important for angiogenesis at 
the site of injury.  MCs will also release cytokines that recruit and activate fibroblasts that will 
eventually participate in fibrous encapsulation.
69
 
 
 
Figure 1.8. Schematic of inflammatory response process that takes place when a sensor, such as 
a glucose sensor, is placed subcutaneously.  The increase in inflammatory cells in the area and 
the ultimate encapsulation of the device in a fibrous sheath creates a situation where levels of 
the analyte near the sensor surface do not reflect the concentrations in the blood.  
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Following initial protein adsorption and release of proinflammatory agents, neutrophils are 
recruited to the site of implantation and begin attempting to phagocytose and degrade the 
foreign device (in this case, the sensor).
71  This involves the release lysosomal proteases, 
reactive oxygen species, and chemokines that serve as potent signals to recruit cells to the wound 
site.  Neutrophils will persist at the wound for 1–2 days before they are replaced by monocytes/ 
macrophages (monocytes excite the vasculature and mature into macrophages in tissue near the 
site of sensor implantation) and lymphocytes.
71  The macrophages become activated and 
release IL-12 and IL-23, reactive nitrogen and oxygen species (such as nitric oxide (NO), 
superoxides and H2O2), and proinflammatory cytokines.
72  Activated macrophages also 
continue to release chemoattractants to recruit more monocytes/macrophages.  It has been shown 
that there is heterogeneous activation of macrophages, dependent on many factors that include 
the nature of the protein layer present and environmental signals that recruit monocytes from 
circulation.
73  The release of these active agents is intended to kill bacteria at the implantation 
site and biodegrade the foreign material that is in the subcutaneous tissue.  These reactive 
species will additionally damage healthy tissue surrounding the implant and can lead to a state 
of chronic inflammation that ultimately leads to fibrous encapsulation of the sensor.  
As the macrophages adhere to the protein-coated sensor, they undergo a cytoskeletal 
rearrangement in order to spread over the surface of the device.  Adherent macrophages then 
fuse to form foreign-body giant cells (FBGCs) that further attempt to biodegrade the implanted 
device.  After approximately 1–2 weeks, chronic inflammation leads to the deposition of a 
collagen matrix by fibroblasts to encapsulate the implant and isolate it from native tissue.
74   
The collagen layer thickness is partially dependent on factors such as the implant 
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texture, the protein layer adhered to the implant, and cells adhered to the protein layer.  
Additionally, movement of the sensor over time can change the thickness and level of 
inflammation around the implant.  It is important to recognize that the material properties, 
topography, and placement in vivo affect the biological response to the implant, but the 
biological response itself will further influence long-term tissue response.
74  Again, this is a 
complicated and dynamic response that changes over time.  This continuous change creates 
a highly challenging analytical environment in which reliable measurements must be made in 
order to make the use of implanted subcutaneous sensors for in vivo monitoring a clinical reality. 
 
1.4 Strategies for Mediating Biological Response to Implanted Sensors 
The commercial development of implantable chemical sensors for routine blood 
monitoring in humans has, at this point in time, reached an impasse of sorts.  With only three 
commercial subcutaneous glucose sensors approved for limited use and no commercially 
available intravascular sensors, it appears that the combination of problems related to cell 
adhesion, thrombus formation, inflammatory response, etc. yielding poor in vivo sensor 
performance is a formidable challenge to overcome.  Key to ultimate success in this field will 
be developing coatings that can prevent/resist the in vivo biocompatibility issues that play a 
dramatic role in the performance of implanted sensors.  Fortunately, there has been significant 
fundamental research recently to address these issues.  In the following section, new coatings that 
may provide a solution to the dynamic biocompatibility problems that have plagued all in vivo 
sensors developed to date will be discussed.  
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1.4.1 Materials Development for Improved Biological Response to Implanted Sensors 
Considerable research over the last two decades has focused on designing materials that 
can be used to coat or fabricate sensors that are able to reduce the in vivo biological response 
that is responsible for loss of sensor function over time.  An excellent review by Wisniewski and 
Reichert
75 details approaches that have been investigated to modify the materials surface 
properties to achieve this goal.  Briefly, this review discusses use of hydrogels such as 
crosslinked poly(hydroxyethyl methacrylate) (PHEMA) or poly(ethylene glycol) (PEG) that 
allow water-soluble analytes to diffuse to the sensing element, and the hydrophilic nature of 
these materials is thought to improve biocompatibility.  Phospholipid surface modification has 
been used in an attempt to mimic phospholipids present on cells in the body, thereby 
decreasing physiological response toward the sensor.  Another approach is to apply thin Nafion 
(a chemically inert anionic compound that contains both hydrophobic and hydrophilic 
properties) coatings that show little adsorption of molecules from solution or use surfactants 
applied to sensor surfaces that have shown reduced protein adsorption.  The use of natural 
materials such as modified cellulose has been shown to reduce compliment activation, covalent 
attachment of anti-fouling agents such as phenylenediamine, diols, and glycols seems to 
enhance biocompatibility.  Additionally, using diamond-like carbons and controlling the 
topography of sensor coats also enhances biocompatibility and stability over time. 
The development of biomimetic hydrogels for sensor coatings involves PHEMA-based 
membranes with PEG incorporated and crosslinked with tetraethyleneglycol diacrylate.  Such 
a material has been reported by Justin and coworkers.
76  This UV-cured material was applied 
to microdisc electrode arrays, and it was shown that the diffusion coefficient of analyte was 
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decreased, and pH response of the material from 6.1 to 8.8 caused a change in the impedance 
signal obtained.   This material is expected to improve biocompatibility of the coated sensor, 
but tuning of the porosity and crosslinking density is needed to preserve the sensor response.  
Silica based sol-gels (SG) have also been developed
77 that include the incorporation of either 
PEG (SG-PEG), heparin (SG-HEP), dextran sulfate (SG-DS), Nafion (SG-NAF), or 
polystyrene sulfonate (SG-PSS).  The composite materials have been tested for toxicity in vitro 
with fibroblast cultures.  The effect on cell proliferation was dependent on which additive was 
included. SG-DS showed the most promising results as glucose sensor coating when tested in 
BSA and serum, slowing the growth of fibroblasts on the surface of the hybrid material, while 
also allowing the best glucose response when coated on an amperometric sensor. 
Work focused on controlling topography and stability of sensor coatings by Ju and 
coworkers
78 includes the development of a 3-dimensional porous type-I collagen scaffold 
crosslinked by nordihydroguaiaretic acid  (NDGA) or glutaraldehyde (GA) that was applied to 
subcutaneous glucose sensors that were implanted for up to 28 days.  The NDGA crosslinked 
collagen coatings showed a decrease in inflammation compared to bare implanted sensors. 
Wang and coworkers
79 developed electrospun fibroporous polyurethane coatings for 
implantable glucose sensors.  The authors were able to control the dimensions of the electrospun 
fibers and their density on the sensors to secure certain advantages including a stronger 
mechanical stability, a greater ability to elongate to accommodate the swelling enzyme layer on 
the sensor, a reduction in mechanical weak spots along the length of the coating, fibers that have 
excellent interconnected porosity, and a fiber structure that mimics natural extracellular matrix 
structure.  Although this material has not been tested in vivo yet, the authors point out that 
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in vitro sensor performance was not adversely affected by the electrospun coating, and there 
is huge potential to apply biomimetic electrospun fibers to sensors once functioning of the fiber 
coating is validated.  Ai, et al.
80 developed a perfluorocarboxylic acid ionomer (PFCI) that 
showed reduced cracking compared to the commonly used perfluorosulfonate ionomer 
membrane (PFSI).  The advantage was realized because PFCI possess higher crystallinity and 
smaller ion clusters compared to PFSI, thereby reducing mineralization in vivo and reducing 
cracking, while maintaining the inert benefits of perfluoro materials. 
 
1.4.2 Active Releasing Materials for Controlling Biological Response 
 
Although the development of static materials that are more cognizant of potential biological 
response and biocompatibility problems is useful, it is unlikely that changing the chemistry 
of the material itself will alleviate biofouling and subsequent sensor failure when placed in 
the harsh, dynamic physiological environment.  Work has also been undertaken that relies on 
more biomimetic approaches such as inclusion of specific surface active agents such as CD47 
and drug eluting materials, both targeted at controlling explicit aspects of the inflammatory 
response. Stachelek, et al.
81 developed a material that appended a recombinant CD47 to 
poly(vinyl chloride) (PVC) or Tecothane, a polyether polyurethane (PU).  CD47 is a 
transmembrane protein that binds to specific receptors on leukocytes and macrophages, which 
causes a downregulation of inflammatory cell attachment.  The CD47-PU material was tested 
in a rat subdermal implant model for 70 days and showed significantly reduced number of 
attached cells associated with both acute and chronic inflammation.  Chapter 3 in this thesis 
details preliminary results of demonstrating the functionalization of polyurethane outer coatings 
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on intravenous glucose sensors through immobilized recombinant CD47 protein does not affect 
the sensors’ amperometric response to glucose,  a collaborative research effort between the 
Stachelek and Meyerhoff research groups. 
Several researchers have also proposed development of systems that will release the anti-
inflammatory agent, dexamethasone (DX), and/or the angiogenic agent, vascular endothelial 
growth factor (VEGF).  Norton et al.
82 developed a hydrogel system based on 2-hydroxyethyl 
methacrylate that released both DX and VEGF.  The idea was to decrease inflammation and 
encourage angiogenesis around an implanted glucose sensor.  Decreasing inflammation 
should decrease the thickness of the fibrous capsule and allow a stable background current to 
be reached more quickly, and increasing vasculature should help increase glucose flux to the 
sensor.  It was found that DX alone did decrease inflammation after 2 weeks of implantation 
in rats.  VEGF alone did increase vascularity of the fibrous capsule, but when DX and 
VEGF are released at the same time from the hydrogel, while there is still a decrease in 
inflammation, there is no increase in vascularization.  After six weeks, there is no observable 
difference between the drug-releasing hydrogels and control implants, indicating that the 
positive effect is not maintained once the drug- release reservoir is depleted.  Sung et al.
83 then 
investigated a similar approach by sequentially delivering DX and VEGF from a crosslinked 
PEG.  The release of DX is faster (kDX ¼ 0.5/day) and VEGF is slower (kVEGF ¼ 
0.4/day).  The difference in delivery rate is enough to see a marked decrease in inflammation 
and increase in vascular density in an ex ova chick embryo after 8 days.  This is significant 
because it points to the temporal importance of delivering agents in the appropriate sequence, 
thus more closely mimicking normal physiological conditions. 
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Bhardwaj and coworkers
84 tested the temporal effect of DX over much longer term implants 
by fabricating different poly(lactic-co-glycolic acid) (PLGA) microspheres that release DX 
for 30 days or PLGA/poly(vinyl alcohol) (PVA) composite microspheres that release DX 
over a 3-month period.  The microspheres were implanted in rats to test for both acute and 
chronic inflammation.  Sustained release of DX was achieved by combining microspheres, and 
the continued release did show suppression of inflammation for 3 months, while spheres that 
exhausted their drug after 30 days lost the ability to decrease inflammation. The same group 
then modified this approach and developed a system that dispersed PLGA microspheres in 
a crosslinked PVA hydrogel.
85  The motivation for this was that many different drugs in 
addition to the DX that was tested could be encapsulated in PLGA microspheres to impart a 
wide array of drug-release capability, and the PVA allows both analyte to diffuse to the sensor 
surface and drug to diffuse into the tissue immediately surrounding the sensor.  The ‘‘smart’’ 
PLGA microsphere/PVA composite system showed good proof of concept tissue response 
when tested in both type-1 and type-2 diabetic rats for 1 month.  Importantly, this system 
also recognizes the importance of tailoring the implanted material to the site of implantation 
and the specific medical condition under which the sensors are being used and holds the potential 
for incorporating additional biological mediators into the sensor coating. 
Another very promising active agent for release from implanted sensors is nitric oxide 
(NO).  Nitric oxide is a free radical-gas that is released endogenously in many physiological 
processes.
86  Namely, within the context of indwelling sensors, NO is a potent antithrombotic 
agent
87 and plays a role in mediating the inflammatory response in subcutaneous tissue.
88  NO 
is an important signaling molecule in shifting inflammation from acute stages to potentially 
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helping in enhancing wound healing.  If NO can be released from intravascular or subcutaneous 
sensors at the appropriate levels and with good temporal control, evidence suggests that NO 
may radically reduce the biological response to these indwelling sensors.
89  A class of NO 
donor that has been extensively used for improving the biological response toward implanted 
sensors is diazeniumdiolates.
87–90  Figure 1.9 shows the structure of some examples of these 
molecules that have been used in polymeric materials to impart NO release to materials for sensor 
fabrication.  Each diazeniumdiolate molecule will release 2 molecules of NO via thermal 
decomposition at 37 °C or a proton-mediated decomposition mechanism.  The rate of 
decomposition can be controlled by changing the molecular structure of the parent compound 
used to form the diazeniumdiolate and/or by tuning the water uptake and pH of the polymer 
matrix in which the molecule is embedded.  Initial work dispersed (Z)-1-[N-methyl-N-[6-(N-
methylammoniohexyl)amino]]-diazen-1-ium-1,2-diolate (DMHD/N2O2), evenly through a PDMS 
matrix coated on an amperometric oxygen  sensor.
90   This material showed greatly reduced 
thromobogenicity, but it was found that the hydrophilic DMHD/N2O2 leached out of the 
polymer matrix, presenting potential problems by allowing the parent diamine compound 
used to form the diazeniumdiolate (and present after NO release) to circulate in the body.  
Some diamine compounds are known to be carcinogenic.
91
 
Because of the extremely promising results for inhibiting thrombus formation on the 
surface of the blood contacting device, work began to either covalently link the NO donor to 
the backbone of the polymer matrix used or to make the donor lipophilic enough that it would 
not exit the hydrophobic polymer matrix to enter the aqueous environment of blood.   
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Figure 1.9.  Chemical structures of two diazeniumdiolate type NO donor species that can be 
incorporated into polymers to coat implantable sensors, creating NO release surfaces that can 
reduce activation and adhesion of platelets in the blood stream and also decrease inflammatory 
response for subcutaneous sensors. (A) diazeniumdiolated dimethylhexanediamine; (B) 
diazeniumdiolated dibutyhexanediamine (DBHD/N2O2). 
 
To this end, modified PDMS materials were developed that contained pendant secondary 
amines that could be converted to diazeniumdiolates and result in materials with different NO 
release properties.  Zhang and coworkers
92 developed DACA/N2O2 and TACA/N2O2 PDMS 
that used diamine and triamino-containing crosslinking agents to react with hydroxyl-
terminated PDMS chains.  Once the crosslinked polymer was cured, it could be converted to 
the diazeniumdiolate by reacting in 5 atm of NO.  Polyurethanes capable of releasing NO 
were reported by Reynolds, et al.
93  They developed two different methods to synthesize 
polyurethanes, containing pendent amines in different positions along the backbone of the PU 
that could be diazeniumdiolated, and these polyurethanes released NO for up to 6 days in 
aqueous solution at 37 °C.  Underivatized PDMSs and PUs are routinely used as membranes 
for sensors (O2, CO2, glucose, lactate, etc.) and hence, adding the NO release capability to 
these polymers should be useful for improving the biological response to indwelling sensors. 
Another approach to impart NO-release properties to polymers used for sensor fabrication 
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is to develop a more lipophilic analog of DMHD/N2O2 that replaces the methyl side groups 
with butyl side groups (DBHD/N2O2)
94 in an effort to alter the partition coefficient enough to 
keep the NO donor within the PDMS matrix in which it is dispersed.  There are two distinct 
advantages to blending a discrete NO donor into the polymer matrix being used to fabricate a 
sensor over modifying materials to covalently attach NO donors.  First, it provides the ability 
to alter the amounts of the NO donor blended into the material, depending on the level and 
reservoir of NO donor desired for a given application.  Secondly, the base polymer matrix can 
be varied without changing the fundamental synthetic chemistry of the polymer itself.  A 
limitation to this approach, however, is that the NO donor can still diffuse out of the polymer, 
albeit a greatly reduced risk compared to DMHD/N2O2.  This diazeniumdiolate chemistry 
using DBHD/N2O2, modulated through pH control by poly(lactic acid) and a polyurethane top-
coat, can be used to impart NO release from needle-type glucose sensors, thus bestowing 
thromboresistant properties to the sensors for intravenous implantation.  In vivo analytical 
performance of these sensors is assessed in both 7 h rabbit models as well as 20 h pig 
experiments and is detailed in Chapter 4 of this dissertation. 
An alternative, which allows similar advantages but reduces leaching, is the development 
of derivativized particle fillers with NO-releasing surface chemistry, such that these particles 
could be incorporated into different polymers, thereby imparting NO release capability to the 
material without changing the fundamental chemistry used to synthesize the matrix.  These 
particles also have a much higher potential loading capacity and release of NO owing to the 
fact that they have more potential NO donating groups than just single molecules.  Zhang and 
coworkers
95 developed a series of silica particles modified by covalent attachment of 
alkylamines to their surface that could be converted into diazeniumdiolates and subsequently 
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blended into different polymers.  This yielded mechanically entrapped NO donors that were 
unable to leach from the polymer surface.  Frost and Meyerhoff
96 also developed fumed 
silica particles derivatized with different S-nitrosothiols, another class of NO donor (e.g., S-
nitroso-cysteine, S- nitroso-N-acetylcysteine, and S-nitroso-N-acetylpenicillamine, or SNAP) 
that could impart NO-release ability with different release profiles compared to the 
diazeniumdiolate-based particle/polymer composites in response to Cu1, or visible light when 
blended into plasticized PVC films.  Although SNAP-based NO release as a solid outer layer is 
not easily transferable directly to glucose sensors, silicone rubber or PU catheters that have been 
impregnated with SNAP can be used to house implantable glucose sensors for intravenous 
placement.  The thromboresistant behavior of these SNAP catheters can then preserve analytical 
accuracy of the sensors either by serving as an outer barrier between whole blood and the 
sensor’s active cavity or potentially through transient NO, which can partition into the 
polyurethane outer coatings of the needle-type sensors during a flush of saline (since NO is 
rapidly scavenged by hemoglobin when whole blood is present).   
There has also been extensive work to develop NO-releasing sol-gels (i.e., xerogels) for 
potential implantable sensor applications.
97–100 Shin and Schoenfisch
97 note that these are 
attractive materials because they are synthesized under mild conditions and are chemically 
flexible and generally porous, facilitating diffusion of analytes through the matrix to the sensor.  
Marxer and coworkers
98,99 
report the synthesis of sol-gels prepared by the hydrolysis and 
condensation of amine-functionalized alkoxysilanes and alkyl- trimethoxysilanes. 
The crosslinked materials were exposed to 5 atm of NO to form diazeniumdiolate moieties 
covalently linked to the material. Four different aminosilanes (isobutyltrimethoxysilane, 
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(aminoethylaminomethyl)-phenethyltrimethoxysilane, (aminohexyl)aminopropyltrimethoxy-
silane and N-[3-(trimethoxysilyl)propyl]diethylenetriamine) all had different storage and 
release properties, demonstrating the ability to achieve a wide range of NO- release profiles 
from this class of material.  Shin et al.
100 embedded NO-releasing sol-gel particles into a 
polyurethane matrix to use as an NO-release coating for glucose sensors.  Roughly 10–200 µm 
NO-releasing particles were obtained by grinding cured sol-gel monoliths synthesized by 
using (amino- hexyl) aminopropyltrimethoxysilane reacted with methyltrimethoxysilane or 
isobutyltrimethoxysilane.  This further demonstrates the utility of these materials and the 
approach of incorporating NO release particles into a wide variety of polymer matrices to 
obtain composite materials that are able to release physiologically relevant levels of NO. 
These materials that release bioactive agents show immense promise in controlling and 
mediating biological response around implanted sensors.  One limitation all these materials 
possess, however, is a finite reservoir of active agent that is able to be released from materials 
preloaded with molecules such as VEGF, DX or NO.  Since these materials also release their 
agents continuously once release is initiated, this limits the lifetime of a device.  NO is, 
consequently, released even when it may not be needed to limit thrombosis, or even when a lower 
level of release may be adequate, and thus the total reservoir is exhausted sooner than need be.  
This unnecessary NO release limits the effective lifetime of the sensor. 
In an effort to impart dynamic control over the level of NO released, RSNO- derivatized 
fumed silica particles imbedded in a hydrophobic polymer matrix showed dynamic NO release 
when illuminated with different intensities of light.
101  The hydrophobic polymer matrix 
excludes transition metal ions and ascorbate ions such that NO release is only initiated by 
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illumination, thereby providing a dynamic “on” trigger for controlling NO release.  
Gierke et al.
102
  have developed a modified polydimethylsiloxane with S-nitroso-N-acetyl-
penicillamine (SNAP-PDMS) covalently attached to the crosslinking agent used to form the 
PDMS.  This material, when coated onto declad optical fibers, enables the precise control over 
the level and duration of NO released in response to a programmed sequence of light generated 
by a wirelessly controlled LED light source (see Figure 1.10).103  This system will permit 
control over NO release and allow detailed information to be obtained regarding the level and 
duration of NO needed to ensure controlled biological response in both blood contacting and 
tissue contacting sensor applications.  Riccio and coworkers
104,105 
developed RSNO-containing 
xerogels that also releases NO in response to illumination using incandescent bulbs of different 
wattages.  These types of materials that are able to release NO in a dynamically controllable 
manner may offer a means to more closely mimic the physiological release of NO and have 
the potential to allow implanted sensors to reach a stable, interfacial blood/tissue response that 
may ultimately allow for widespread clinical utility. 
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Figure 1.10. NO generated from S-nitroso-N-acetylpenicillamine-polydimethylsiloxane 
(SNAP-PDMS) coated on declad region of a 500 mm poly(methyl- methacrylate) (PMMA) 
optical fiber with drive current turned on and off and increasing with each step.  The pulses used 
in this example were in 4 min intervals, light off and then light on with increasing light applied 
in each subsequent step from 2, 5, 10, 15 and 20 mA of Idrive applied and then 15, 10, 5, 2, 
and 0 mA applied to the LED via the ED. The corresponding surface fluxes of NO generated 
was 0.95 ± 0.04, 1.50 ± 0.13, 2.37 ± 0.33, 3.19 ± 0.45, 3.88 ± 0.57, 3.13 ± 0.13, 2.30 ± 0.19, 
1.42 ± 0.12, and 0.91 ± 0.04 (allx10–10 mol · cm
–2 · min
–1
), respectively.  The inset shows that 
the surface flux of NO generated is linearly related to the drive current applied to the LED 
illuminating the coated optical fiber and is identical whether Idrive is applied form 0–20 mA or 
20–0 mA.  Measurements were made at 22 °C with chemiluminescence detection. (From ref. 103 
with permission.) 
 
1.4.3 Materials to Mimic Biological Form and Function  
To more fully mimic biological tissue such as intact endothelium, Zhou and Meyerhoff
106 
created a trilayer system that combined NO release with surface-immobilized heparin.  The idea 
is to more closely mimic the dual action of antiplatelet NO and anticoagulant heparin.  Wu and 
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coworkers
107 later combined a continuously releasing NO PurSils layer top coated with a 
CarboSil® with surface-bound thrombomodulin and heparin that were shown to be biologically 
active.  As material development produces more matrices that exhibit better biocompatibility, 
it is likely that combining these improved materials properties with controlled active agent release 
and immobilized bioactive molecules will lead to greatly enhanced performance of indwelling 
sensors. 
An additional step toward creating longer-term implants would be to eliminate the 
dependence on the reservoir of active agent present in the implanted device.  Klueh and 
coworkers
108 developed a system in which they genetically engineer cells to produce excess 
levels of VEGF.  These cells were entrapped in the tip of a glucose sensor.  The goal was to 
increase vascularization around the implanted sensor to allow ample diffusion of glucose to the 
sensor.  When implanted in ex ova chick embryos, they were able to demonstrate a dramatic 
increase in the density of blood vessels present around the implant.  This approach relies on 
the production of VEGF by cells in situ rather than a preloading of the sensor with the active 
agent.  Another approach to avoid preloading donor molecules was demonstrated by Oh and 
Meyerhoff.
109 They developed a lipophilic catalytic copper-containing species that was 
incorporated into poly(vinyl chloride) (PVC) and demonstrated that RSNOs present in the 
bathing solution surrounding the material were decomposed to release NO catalytically.  
Hwang and Meyerhoff
110 then took a similar copper cyclen structure and tethered it to the 
surface of biomedical-grade polyurethane that was capable of spontaneously generating NO 
when in contact with blood.  This approach offers the advantage of using already existing 
medical grade polymers and imparting them with NO-release properties.  Cha and 
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Meyerhoff
111 then extended this by developing an immobilized organoselenium moiety that was 
able to catalytically generate NO from RSNOs present in plasma.  These catalytic systems 
should be capable of nearly indefinite production of NO from their polymer surfaces because 
RSNOs are endogenously produced in the body and circulate in blood and intestinal fluid.  As 
long as adequate levels of the endogenous RSNOs and reducing equivalents are present, the 
material will continue to generate physiological NO levels at the polymer/biological interface. 
 
1.5 Summary 
The goal of developing implantable blood gas, glucose, and lactate sensors that can 
provide reliable, real-time clinically relevant results remains elusive.  While great advances 
have been made in the development of miniaturized electrochemical and optical sensors that 
have adequate sensitivity, selectivity and stability when operated in vitro, the placement of 
such devices in the in vivo environment creates a physiological response that greatly 
influences the quality of analytical results obtained.  As summarized above, progress in this 
area mandates the development of appropriate sensor coating materials that can mitigate the 
normal activation of platelets and other cells when devices are placed intravascularly and the 
inhibition of the inflammatory response when sensors are placed subcutaneously.  These 
coatings must be capable of diminishing the normal physiological responses to the implanted 
sensors, yet they cannot adversely affect analytical response properties, including response 
times, sensitivity to the target analyte, and selectivity of the sensor.  A wide range of new, 
passive and active biomaterials coatings have been devised in recent years specifically to target 
the in vivo sensing challenge. In the end, it is likely that a combination of immobilized 
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agents and slow chemical release strategies will be needed to resolve the physiological response 
issues that have limited the analytical performance of implanted sensors to date.  Continued 
research in this area during the coming years will hopefully achieve success and provide an 
array of new in vivo sensor tools that will enhance the quality of health care and disease 
management for millions of people worldwide. 
1.6 Statement of Dissertation Research 
In this thesis, a number of the strategies outlined above are selected with the intention of 
enhancing the biocompatibility of needle-type glucose sensors ultimately intended for 
intravenous implantation to aid in the tight glycemic control of ICU patients.  Chapter 2 
specifically details application of an annealed Nafion inner rejection layer on an inner Pt/Ir 
electrode surface area to enhance glucose sensor’s selectivity over the electroactive 
interference species commonly encountered in whole blood.  Daily assessment measurements 
of this layer’s selectivity, specifically against ascorbic acid, uric acid, and acetaminophen were 
conducted yielding data supporting the hypothesis that the annealed Nafion layer maintains the 
sensor’s selective behavior for at least 8 d, with less degradation in an aqueous buffer 
environment than a non-annealed Nafion counterpart layer.   
Chapter 3 reports initial findings for a new collaborative research between the Meyerhoff 
lab (University of Michigan) and Dr. Stanley Stachelek (Children’s Hospital of Philadelphia) 
aimed at functionalizing the outer polymer coating of the implantable glucose sensors with 
recombinant CD47 protein.  This approach will potentially impart a “self” marker to the sensor 
surface, ultimately camouflaging it from foreign body response cells bearing the signal 
recognition transmembrane protein α (SIRPα).  Preliminary data in Chapter 3 indicates that 
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glucose sensors can be successfully functionalized with recombinant CD47, and that the 
sensors retained their glucose linearity and glucose oxidase activity throughout the complete 
functionalization procedure. 
Poly(lactic acid) layers containing dispersed diazeniumdiolates have been previously 
reported to provide NO release functionality to needle-type glucose sensors, and in vivo 
measurement within 7 h rabbit experiments.112  Continuous measurements, in the form of a 
concentration vs. time trace plots are reported in Chapter 4 for sensors fabricated with this NO 
release chemistry and a new type of polyurethane outer coating (E2As Elast-eon).  Further 20 
h continuous measurements are reported for such sensors implanted within porcine blood 
vessels.  Due to the difficulty with obtaining analytically accurate measurements in the latter 
case, long term in vitro stability measurement were conducted in bovine serum, and extensive 
in vitro testing for possible interference from administered intravenous drugs and NO 
scavenging effects from hemoglobin are reported via in vitro  measurements in heparinized 
blood. 
Chapter 5 summarizes efforts on a collaborative project with Edwards Life Sciences aimed 
to impart NO release capability to an existing commercial device designed for intermittent in 
vivo glucose measurement.  Though the glucose sensors are fabricated without inherent NO 
release functionality, preliminary data in Chapter 5 shows that during the phase when the 
catheter housing the sensor is flushed with a buffered calibration solution, NO released from a 
surrounding catheter (which was previously impregnated with SNAP chemistry) can partition 
into the extremely thin polyurethane outer coating of the glucose sensor, and subsequently 
provide transient NO release behavior immediately afterward.  Since the Edwards product 
measures glucose in blood only intermittently (every 5 min) by retracting blood over the sensor 
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housed potentially within an NO release catheter, this approach may provide adequate 
anticoagulant activity vs. using heparin within the calibration solution (current approach) that 
bathes the sensor when blood is not retracted over it.  
Ultimately, while several of these projects are still within the preliminary data collection 
phase of in vivo evaluation, the data presented herein indicates the potential of annealed Nafion 
selective membranes, sensor surface CD47 functionalization, active NO releasing sensor 
surfaces, and transient NO release from an active surrounding catheter as viable 
biocompatibility/selectivity enhancement strategies to improve in vivo glucose sensor lifetime 
and performance. 
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CHAPTER 2 
IMPROVED GLUCOSE SENSOR SELECTIVITY OVER ELECTROACTIVE 
INTERFERENCE SPECIES WITH ANNEALED NAFION 
 AS AN INNER REJECTION LAYER 
2.1  Introduction 
As highlighted in Chapter 1, accurate real-time measurement of blood glucose levels within 
critically ill hospital patients in intensive care units is a niche that can be filled by the development 
of intravenous blood glucose sensors.  Such monitoring could not only decrease potential 
complications for diabetic patients, but also offers better outcomes for non-diabetic patients, both 
benefiting from tight glycemic control.  Miniaturized glucose sensors have been developed in 
academic labs for intravenous use and in commercialized products for measurement in 
subcutaneous interstitial/brain fluid matrices; however, achieving good biocompatibility and high 
selectivity over potential interference species are the primary obstacles that have prevented 
widespread clinical applications of such intravascular devices for ICU patients.  
First generation glucose sensors function by electrochemical oxidation of hydrogen peroxide 
(H2O2) produced by the glucose oxidase enzyme which is immobilized onto the sensor surface.  In 
the absence of inner selectivity enhancement layers, the steady-state current generated from the 
oxidation of H2O2 is proportional to the bulk glucose concentration in the buffered solution, blood, 
or fluid surrounding the sensor.  However, other naturally-occurring electroactive species 
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(ascorbate and urate) are present in biological fluids, and these are typically oxidized at the 
operating potential of such glucose sensors (e.g., +0.600V vs. Ag/AgCl reference), creating an 
overall oxidation current in which it is difficult to distinguish the component currents of each 
individual oxidation reaction.  Without using methods to achieve preferential oxidation of H2O2 
generated from glucose at the working wire electrodes of such devices, the accuracy of these 
glucose sensors is poor, yielding falsely elevated values for glucose in the blood or subcutaneous 
fluid. 
Previous glucose sensor designs have featured two types of selectivity enhancing layers.  The 
first layer, is typically a coating of Nafion that provides selectivity against negatively-charged 
electroactive species, such as ascorbate and urate.  The second layer is an electropolymerized film 
formed by the oxidation of the monomers 1,3-diaminobenzene and resorcinol, which forms on an 
inner Pt/Ir electrode surface only within the pores in the Nafion layer.  This electrochemically 
formed polymer layer is designed to select based on size-exclusion, reducing the oxidation signal 
generated from the neutrally-charged electroactive interference species such as acetaminophen, an 
analgesic commonly administered to hospital patients.  A variety of electropolymerized films were 
examined in the work reported by Carelli, et al. in 1993 by exploring a range of scanning potential 
ranges, scan rate, polymerization time duration, and composition of monomers which were 
subsequently ranked by their selectivity of H2O2 oxidation over ascorbate, urate, and 
acetaminophen.1  In 2011, Yan, et al. adapted a specific electropolymerized film protocol 
(monomers, potential scan range, scan rate, reaction duration) for use as a selective layer for 
implantable glucose sensors.2  The electropolymerization process occurred over 18 h using 
repeated cyclic voltammetric scans (range: 0.000 to +0.830V vs. Ag/AgCl reference; scan rate: 
0.002 V/s), and the progress of the reaction was monitored by observing the decreasing peak 
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current, indicating the formation of a non-conducting polymer on the sensor surface.  However, 
these electropolymerized films are vulnerable to partial structural decomposition with sustained 
exposure to aqueous solutions and can gradually lose selective functionality over time. 
Kwon, et al. demonstrated, on a macro scale, that annealing Nafion films (~50-170mm 
thickness) above their glass transition temperature range (above the 100-150°C) causes significant 
change in conducting ionic channel structure and the ionic activity at the membrane surface.3  To 
date, there are no published findings on application of such annealed Nafion layers for use in 
creating in vivo glucose sensors with enhanced selectivity.  In this chapter, the concept of utilizing 
an annealing process of thin Nafion films, pre-applied to the glucose sensors before application of 
electropolymerized films, is shown to enhance selectivity over ascorbate and urate, indicating less 
structural decomposition, and ultimately, extended glucose sensor lifetimes. 
2.2  Experimental 
2.2.1  Materials 
Glucose oxidase (Type VII, from Aspergillus niger), d(+)-glucose, glutaraldehyde, bovine 
serum albumin (BSA), iron (III) chloride (FeCl3), 37% hydrochloric acid (HCl), L-ascorbic acid, 
uric acid (sodium salt), acetaminophen, Nafion (5 wt % solution in lower aliphatic alcohols/H2O 
mixture), 1,3-diaminobenzene, resorcinol, tetrahydrofuran (THF), N,N’-dibutyl-1,6-
hexanediamine (DBHD) were all obtained from Sigma-Aldrich (St. Louis, MO).  Sodium 
phosphate dibasic heptahydrate (Na2HPO4 · 7H2O), sodium phosphate monobasic monohydrate 
(NaH2PO4 · H2O) were purchased from Amresco, Inc. (Solon, OH).  Sodium chloride (NaCl) is a 
product of Research Products International Corp. (Mt. Prospect, IL).  Potassium chloride is from 
Fisher Scientific (Pittsburgh, PA).  Teflon-coated platinum/iridium and silver wires are products 
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of A-M Systems (Sequim, WA).  E2As Elast-Eon polyurethane was a gift from Aortech 
Biomaterials.  Diazeniumdiolated DBHD (DBHD/N2O2) was synthesized by treating DBHD with 
80 psi nitric oxide (NO) gas purchased from Cryogenic Gases (Detroit, MI) at room temperature 
for 24 h, as previously described.4 
2.2.2  Sensor Fabrication 
Glucose sensor design (see Fig. 2.1) was based on previous configurations2,4-6 by first cutting 
a 1-mm length cavity in the Teflon coating of a platinum/iridium wire (outer diameter = 0.2 mm).  
A Nafion coating was then applied to the cavity, and then the wires were annealed at 170°C for 
1.5 h and then gradually cooled to 35°C using a Fisher Scientific Isotemp oven to enhance sensor 
selectivity against negatively-charged electroactive interference species, such as ascorbic and uric 
acid.  Control sensors were dried at 37.5°C, rather than annealed.  Then via a CV 
electropolymerization process (cycling voltage between 0 and +0.830 V at 0.002 V/s for 18 h) a 
layer of polymerized resorcinol and m-phenylenediamine2,7 was applied to the cavity to help 
further reject electroactive neutral interference species, such as acetaminophen, from reaching the 
inner Pt/Ir surface.  A silver/silver chloride (Ag/AgCl) wire electrode was tightly wrapped around 
the sensor to serve as an electrochemical reference, and heat-shrinkable polyester tubing was 
applied to secure the reference wire in place. Glucose oxidase was then immobilized within the 
cavity using glutaraldehyde.  An outer polymer layer was then applied to the sensor’s surface using 
a wire loop: a 2% (wt/vol) Elast-Eon E2As polyurethane in THF was applied as a top coat to 
modulate the NO release and also control the sensor’s linear detection range for glucose by 
restricting glucose diffusion into the immobilized enzyme layer.  E2As polyurethane was chosen 
for these studies since it had been previously used with positive success as an NO release coating 
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to prevent platelet activation and clotting within a rabbit model for extracorporeal circulation.8  A 
diagram of the fully-assembled sensor is shown below in Figure 2.1.   
 
Figure 2.1.  Configuration of annealed Nafion-based intravascular glucose sensor with expanded 
inset of electroactive interference rejection layer. 
2.2.3  Analytical In Vitro Performance of Annealed Glucose Sensors 
Glucose sensors were calibrated using 4-channel BioStat potentiostats (ESA Biosciences Inc., 
Chelmsford, MA).  The potential applied to the inner Pt/Ir wire was +0.600 V vs. Ag/AgCl 
reference in a 0.1 M phosphate buffered saline (PBS), pH 7.4, test solution at 37.5°C. 
To evaluate the selectivity of the sensors over naturally occurring electroactive interference 
species such as ascorbic acid, uric acid, and acetaminophen, injections of near maximum in vivo 
concentrations of these species were made into the in vitro test cell (thermostat-controlled glass 
beaker) during the glucose calibrations (from 1.0 – 20.0 mM).  The % error for these sensors was 
calculated by dividing the current response from an injection of interference species (0.5 mM for 
ascorbic acid, 0.33mM for uric acid, and 0.2 mM for acetaminophen9 by the current signal recorded 
for 5.0 mM glucose, the average normal level of glucose in blood.  A threshold was established to 
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determine effective selectivity: the current from a specific interference species should not exceed 
5% of the current response observed for 5.0 mM glucose10.  The selectivity test was repeated and 
monitored over 14 days to evaluate the stability of the selectivity layers.  Comparisons in stability 
were evaluated between sensors with the annealed Nafion layers and the control group of sensors, 
which were fabricated with non-annealed Nafion. 
2.2.4  Additional In Vitro and In Vivo Evaluation of Annealed Glucose Sensors 
Some experimental results detailed in Chapters 3 and 4 of this thesis document continued to 
use the annealed Nafion layer for extended selectivity over interference species due to the 
conclusions drawn from results presented in this chapter.  
2.3  Results and Discussion 
2.3.1  Extended In Vitro Glucose Sensor Stability 
Figure 2.2 displays a selectivity comparison of eight glucose sensors prepared with annealed 
Nafion layers and six glucose sensors fabricated with non-annealed Nafion layers over ascorbic 
acid through an experimental period of 8 d.  The values for selectivity represent the average change 
in sensor response current for an injection of 0.5 mM ascorbic acid, the maximum biological 
concentration, divided by the current change recorded for an injection of 5.0 mM glucose.  The 
line at 0.05 represents the 5% threshold for selectivity tolerance for a sensor over a particular 
electroactive interference species.  For the glucose sensors made with annealed, Nafion, selectivity 
under the selectivity threshold for ascorbic acid is maintained for the duration of the testing.  These 
sensors also have a lower variability in their selectivity, which is maintained throughout the testing 
period.  
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Figure 2.2.   In vitro comparison of selectivity over ascorbic acid (0.5 mM) between glucose 
sensors fabricated with annealed Nafion layers and those with non-annealed Nafion layers. 
 
Figure 2.3 highlights the selectivity comparison of the same eight annealed Nafion glucose 
sensors versus six non-annealed glucose sensors over uric acid, another common electroactive 
interference species found in blood and bearing a negative charge.  The glucose sensors fabricated 
with annealed Nafion sensors maintain excellent selectivity (< 3%) with a very tight standard 
deviation, accounting for variation between different sensors, for the duration of the 8 d of testing.  
In contrast, those glucose sensors with non-annealed Nafion layers have a larger variability in their 
responses, and some do cross the 5% threshold of interference species response during the 
evaluation period. 
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Figure 2.3.   In vitro comparison of selectivity over uric acid (0.44 mM) between glucose sensors 
fabricated with annealed Nafion layers and those with non-annealed Nafion layers. 
  
Figure 2.4 compares the selectivity of the eight annealed Nafion glucose sensors with non-
annealed sensors over acetaminophen.  A common analgesic, acetaminophen is not a naturally 
occurring species, but may be present in hospitalized patients, which is the target application for 
intravenous CGM sensors.  It is a neutral molecule, and is primarily selected against by the size 
exclusion properties of the electropolymerized layer of the glucose sensors.  Interestingly, several 
commercial subcutaneous CGM systems encourage users of their glucose sensors to refrain from 
consuming acetaminophen while using the system, especially during their periods of instrument 
calibration.11  Both the annealed and non-annealed sensors in Figure 2.4 have similar selectivity 
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against acetaminophen throughout the testing time, although the standard deviation, indicating 
variability between the sensors, is smaller for the annealed sensors.  The dissertation thesis work 
of Dr. Qinyi Yan indicates that  < 7% may be a more appropriate threshold cutoff for signal from 
acetaminophen oxidation.10  Otherwise, hospitalized patients could be given an alternative 
medication for pain relief while using these sensors for blood glucose monitoring. 
Figure 2.4.   In vitro comparison of selectivity over acetaminophen between glucose sensors 
fabricated with annealed Nafion layers and those with non-annealed Nafion layers. 
 
Since the glucose sensors fabricated with annealed Nafion layers maintained better selectivity 
over two of the three major electroactive interference species found in blood than did those with 
previously-described non-annealed Nafion, these experiments indicate that annealed Nafion-based 
glucose sensors can maintain reasonably good selectivity over the expected lifetime of the sensor 
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of approximately 7 d.  The lack of improved selectivity over acetaminophen is likely based on the 
fact that its diffusion through Nafion is not impeded based on the properties of the Nafion layer 
that change as a function of the annealing process, and its access to the underlying Pt/Ir electrode 
is governed more by its permeability through the electropolymerized organic layer.  In particular, 
it appears that the better rejection over ascorbate and urate in the case of the annealed Nafion layer 
may be due to slightly smaller hydrophilic channels within the structure of the Nafion layer that 
are formed by reorganization of the anionic sulfonate groups within Nafion.  Slightly smaller 
channels would enhance the transference numbers for cations vs. anions, especially larger anions 
such as ascorbate and urate.  Recently published studies of Nafion thin films and membranes have 
confirmed physical morphological changes that occur during treatment at elevated temperatures.  
Annealing (at 160°C) commercially-produced Nafion films that were 254 µm in thickness 
demonstrated significant changes in oxygen gas permeability based on morphological changes to 
the hydrophilic channels of the membrane.12  A study of 6-µm thick Nafion films cast on quartz 
slides demonstrated that annealing the films caused distinct physical changes in the hydrophilic 
channels of the membranes, specifically the formation of sulfonic acid anhydrides, as evidenced 
by attenuated total reflection infrared spectroscopy (ATR-IR).13 
2.4  Conclusions and Future Directions 
A major obstacle to continuous glucose monitoring in blood with electrochemical enzymatic 
glucose sensors is the oxidation of electroactive species at the operational applied voltage range 
for the sensor, leading to incorrect glucose readings.  Annealing the Nafion layers of such glucose 
sensors enhances their selectivity, especially over the negatively charged ascorbic and uric acid 
species in comparison to previous sensor designs that included Nafion but did not involve the 
annealing process.  This selectivity enhancement is maintained over the course of at least 8 d, 
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indicating that with regard to the sensor lifetime, such sensors are expected to maintain their 
selective properties to match the duration of nitric oxide (NO) release once additional outer layers 
were added to the sensor surface (see Chapter 4).  The smaller standard of deviation for the 
annealed Nafion sensors, which is also maintained for the 8 d duration, indicates that there is less 
performance variability between individual sensors, 6 
Annealed Nafion has been previously reported to yield much thicker, large scale films for 
other applications (e.g. examining the topographical structure via AFM and ionic channel 
selectivity properties),3 but their application to create improved glucose sensors has not yet been 
reported.  Due to the success of these experiments, further sensors discussed in Chapters 3 and 4 
that employ outer layers to enhance biocompatibility were fabricated with annealed Nafion layers.  
Of particular interest, once the annealed Nafion glucose sensors were combined with NO releasing 
layers, they could be evaluated for glucose measurement performance within heparinized blood in 
vitro on the benchtop, as well as in vivo assessment when implanted within the blood vessels of 
rabbits or pigs. 
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CHAPTER 3 
POTENTIAL FOR ENHANCING GLUCOSE SENSOR SURFACE 
THROMBORESISTANCE BY UTILIZING RECOMBINANT CD47 PROTEIN 
FUNCTIONALIZATION: A PRELIMINARY COMPATABILITY STUDY 
3.1  Introduction 
As highlighted in Chapters 1 and 2, accurate real-time measurement of blood glucose in 
intensive care unit (ICU) patients requires the development of needle-type intravenous blood 
glucose sensors.  Such monitoring not only decreases potential complications for diabetic patients, 
but also offers better outcomes for non-diabetic patients, both benefiting from tight glycemic 
control.  Miniaturized glucose sensors have been developed in academic labs for intravenous use 
and in commercialized products for measuring in subcutaneous interstitial/brain fluid matrices; 
however, biocompatibility is the primary obstacle to widespread use and application. 
As illustrated in Figure 3.1, thrombosis of the sensor surface is a potential problem when the 
device comes into physical contact with fresh, flowing blood.  In blood, the body’s coagulation 
system will quickly respond to the implantation of a foreign material, such as a chemical catheter.  
Surface protein adsorption occurs within minutes, which can lead to the activation of the 
coagulation cascade (e.g., platelet activation) and clot formation around the working area of the 
sensor.  Platelets and red blood cells that compose these clots increase diffusion time from the bulk 
blood to the electrode surface, resulting in increased response times or unpredictable sensor signal 
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drift.  These cells also consume glucose and oxygen, which cause the local concentrations of these 
species to differ from the bulk blood concentrations, resulting in analytical performance errors. 
 
 
Figure 3.1.  Illustration of thrombosis formation on the sensor surface during an in vivo experiment 
(A) and simulation of declining glucose sensor analytical performance after clot formation, as 
compared to benchtop point-of-care device (B). The red squares represent frequent measurements 
made by a continuously or intermittently monitoring glucose sensor, which correlate at the start of 
the experiment with the less frequent, discrete measurements made by the benchtop blood gas 
analyzer.  However, after surface thrombus formation occurs (after 150 minutes), the continuous 
sensor measurements significantly deviate from the blood gas measurements. 
 
One method to prevent clot formation on polymer surfaces is to functionalize the material with 
biocompatible molecules or native proteins, with the goal of camouflaging the implanted device 
against the typical thrombotic response.  Our collaborators, Dr. Robert J. Levy and Dr. Stanly 
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Stachelek, at the Children’s Hospital of Philadelphia have pioneered the attachment of 
recombinant CD47 protein onto poly(vinyl chloride) and polyurethane surfaces and have found 
that such treatment significantly reduces human neutrophil and human monocyte derived 
macrophage attachment to those surfaces, respectively.1  They have further demonstrated that 
reduced platelet and neutrophil activation occurs in blood when contacting CD47 functionalized 
polymer surfaces.2  Naturally-occurring CD47 is a transmembrane protein that is ubiquitously 
expressed in many mammalian cells (Fig. 3.2).  When immune cells or platelets bearing the SIRPα 
transmembrane protein come into contact with the Ig extracellular domain of its cognate ligand, 
CD47, a temporary “handshake” interaction occurs between the CD47 and SIRPα, and prompting 
immune response cells such as thrombocytes, leukocytes, and macrophages to recognize the 
surface as “self” and thus do not trigger pathways activate the immune or the coagulation cascades 
(Fig. 3.3)1.  Initially, CD47 became a protein of interest when it was found to be upregulated in 
malignant cancerous cells, giving the cells “camouflage” or “cloaking” against phagocytosis.3,4  
This resistance to phagocytosis was then successfully transferred to artificial structures such as 
perfluorocarbon emulsions (PFC) and to both µm-and nm-sized polystyrene beads.5-10   More 
recent studies into the specific inflammatory response pathways and mechanisms affected by the 
“handshake” interaction between CD47 and SIRPα show that CD47 provides a global 
inflammatory inhibition, which extends beyond only localized resistance to phagocytosis.11 
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Figure 3.2.  Transmembrane and extracellular domains of naturally-occurring CD47 protein 
(figure adapted from Brown, et al., Trends Cell Biol. 2001).12 
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Figure 3.3.  Concept and molecular mechanism of the temporary “handshake” interaction between 
recombinant CD47 immobilized on a polymer surface and the SIRPα domain found on an 
inflammatory cell membrane (figure adapted from Finley, et al., Biomaterials 2011).1 
Thus, the ability of the CD47 extracellular membrane to confer “self” status to a synthetic 
polymer surface makes it an attractive method of potentially enhancing the biocompatibility of 
implantable catheters and sensors, provided that a sufficient CD47 surface density can be achieved.  
In the case of implantable chemical sensors, it must first be demonstrated that immobilization of 
CD47 on functional sensors does not alter the analytical response of such devices.  In this chapter, 
the glucose sensors described in Chapters 2 that featured outer E2As polyurethane coatings are 
examined for their ability to be surface functionalized with CD47 and the effect of such an 
immobilization process on the electrochemical response to glucose is herein evaluated.   
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3.2  Experimental 
3.2.1  Materials 
Glucose oxidase (Type VII, from Aspergillus niger), d(+)-glucose, glutaraldehyde, bovine 
serum albumin (BSA), iron (III) chloride (FeCl3), 37% hydrochloric acid (HCl), L-ascorbic acid, 
uric acid (sodium salt), acetaminophen, Nafion (5 wt % solution in lower aliphatic alcohols/H2O 
mixture), 1,3-diaminobenzene, resorcinol, tetrahydrofuran (THF), N,N’-dibutyl-1,6-
hexanediamine (DBHD) were all obtained from Sigma-Aldrich (St. Louis, MO).  Sodium 
phosphate dibasic heptahydrate (Na2HPO4 · 7H2O), sodium phosphate monobasic monohydrate 
(NaH2PO4 · H2O) were purchased from Amresco, Inc. (Solon, OH).  Sodium chloride (NaCl) was 
a product of Research Products International Corp. (Mt. Prospect, IL).  Potassium chloride was 
obtained from Fisher Scientific (Pittsburgh, PA).  Teflon-coated platinum/iridium and silver wires 
were products of A-M Systems (Sequim, WA).  E2As Elast-Eon polyurethane was a gift from 
Aortech Biomaterials (Weybridge, Surrey, UK).   
3.2.2 Sensor Fabrication 
The glucose sensor configuration was based upon previous designs13-16 and the devices were 
prepared by first cutting a 1-mm length cavity in the Teflon coating of the platinum/iridium wire 
(outer diameter = 0.2 mm).  A Nafion coating was then applied to the cavity, and then the wires 
were annealed at 170°C for 1.5 h, and then gradually cooled to 35°C using a Fisher Scientific 
Isotemp oven to enhance sensor selectivity against negatively-charged electroactive interference 
species, such as ascorbic and uric acid.  Then via a CV electropolymerization process (cycling 
voltage between 0 and +0.830 V at 0.002 V/s for 18 h) a layer of polymerized resorcinol and m-
phenylenediamine13,17 was applied to the cavity to help reject neutral electroactive interference 
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species, such as acetaminophen, from reaching the Pt/Ir surface.  A silver/silver chloride 
(Ag/AgCl) wire electrode was tightly wrapped around the sensor to serve as an electrochemical 
reference, and heat-shrinkable polyester tubing was applied to secure the reference wire in place.  
Glucose oxidase was then immobilized within the cavity using glutaraldehyde, as previously 
published.13,14,18  An outer polymer layer was then applied to the sensor’s surface using a wire 
loop.  This layer consisted of 2% (wt/vol) Elast-Eon E2As polyurethane in THF and it was applied 
as a top coat to modulate the NO release and also control the sensor’s linear detection range for 
glucose by restricting glucose diffusion into the enzyme layer.  The E2As polyurethane outer 
coating was previously used with success to prepare an NO release inner coating to prevent platelet 
activation and clotting within a rabbit model for extracorporeal circulation.19  Sensors (see Figure 
3.4) were calibrated within the operational range of glucose sensors (1.0 – 20.0 mM) to ensure 
good analytical performance before modification, and subsequently dried before shipping to Dr. 
Stachelek at CHOP for CD47 surface functionalization.  Control sensors that were not CD47 
functionalized were also prepared from the same batch, kept in the University of Michigan 
Chemistry Department, and tested for analytical performance at the same time as the sensors 
modified with CD47 at CHOP to ensure that sensor age did not adversely affect glucose sensor 
response properties. 
A diagram of the fully-assembled sensor is shown below in Figure 3.4: 
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Figure 3.4.  Configuration of annealed Nafion glucose sensors with surface functionalized 
recombinant CD47 protein. 
 
3.2.3  Recombinant CD47 protein production and purification (performed by Dr. Stanly Stachelek 
at the Children’s Hospital of Philadelphia, as described in Finley, et al. Biomaterials 2012).2 
A modification of the previously published methodology was used to produce recombinant 
human CD47 from human whole blood.1,2  Briefly, the extracellular domain of human CD47 
(GenBank accession number NM_174708) was amplified from human cDNA using gene specific 
primers.  Forward Primer: 5’ – ATAAGCTTATGTGGCCCCTGG - 3’. Reverse Primer: 5’ - 
GCGGATCCTCTGGTTCAACCCT – 3’.  The PCR conditions were as follows: 95°C for 30 s 
denaturation, 59°C for 45 s annealing, and 72°C for 1 min extension for a total of 35 cycles.  The 
PCR product was ligated into a thymidine/adenine vector containing the rat CD4 domains 3 and 4 
(rCD4D3+4) coding sequence.  A poly-lysine coding sequence (L) was cloned into the vector at 
the three prime end of the rat CD4 sequence to aid in protein purification and appendage to the 
polymeric surfaces.  The expression cassette (5’ - hCD47-rCD4d3+4-Biotin – 3’ or 5’ - hCD47-
rCD4d3+4-Poly-Lysine – 3’) was then sub-cloned into pcDNA5-FRT (Invitrogen, Carlsbad, CA) 
by digesting vector and insert with Hind III and BamHI and then ligating using T4 DNA ligase.  
All vectors were sequenced by the Children’s Hospital of Philadelphia Research Institute Nucleic 
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Acid Facility and confirmed to be free of coding errors and in-frame for accurate protein 
production.  The pcDNA5-FRThCD47- rCD4d3+4-Biotin (hCD47B) and pcDNA5-FRT-hCD47-
rCD4d3+4-Poly-Lysine (hCD47L) were co-transfected with pOG44, used to transiently provide 
the recombinase enzyme required for integration of the hCD47-rCD4d3þ4 into the genomic DNA 
of the host cell, into CHO Flp-In cells to allow for genomic integration of the expression cassette.  
Recombinant protein was isolated from the cell culture medium, concentrated, desalted, and 
purified using an avidin protein purification column or anti-CD47 amino-link protein purification 
column both obtained from Thermo Fisher Scientific (Wilmington, DE).  Protein concentration 
and purity were analyzed by the Bradford assay and SDS-PAGE Western blot analysis. 
3.2.4  Appending of poly-lysine tagged recombinant proteins to synthetic polymeric surfaces 
(performed by Dr. Stanly Stachelek at the Children’s Hospital of Philadelphia, as described in 
Finley, et al. Biomaterials 2012)2 
Polyurethane coated glucose sensors were reacted with 2-pyridyldithio-, benzophenone- and 
carboxymodified polyallylamine (PDT-BzPh) and reduced with tris(2-carboxyethyl)phosphine 
TCEP to obtain a thiol reactive surface, as previously described.1,2  The poly-lysine tail of the 
recombinant CD47L protein was reacted with succinimidyl 4-(N-maleimidomethyl) cyclohexane-
1-carboxylate (SMCC) for 1 h to form thiol-reactive groups. SPDP was removed via a desalting 
protein cut off column and the poly-lysine CD47 protein was incubated with the synthetic surface 
overnight at 4°C.   Figure 3.5 is provided as an illustration of the chemistry described in this 
section.  Confirmation of recombinant protein attachment was determined by conjugation with a 
FITC-tagged antibody specific for human CD47 (BD Biosciences, Franklin Lakes, NJ).  
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Figure 3.5.  Mechanism of recombinant CD47 functionalization of polyurethane surface coating 
of functional glucose sensors. 
 
3.2.5  Analytical In Vitro Performance of Annealed Glucose Sensors 
Glucose sensors were calibrated using a 4-channel BioStat potentiostats (ESA Biosciences 
Inc., Chelmsford, MA).  The potential applied to the working Pt/Ir wire of the sensors was +0.600 
V vs. Ag/AgCl reference in 0.1 M phosphate buffered saline (PBS), pH 7.4, at 37.5°C.  It was 
critical to measure the sensor response before and after CD47 functionalization, to ensure that 
glucose oxidase activity was retained throughout the CD47 attachment procedure and transit 
between laboratories. 
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As previously described (see Chapter 2), the selectivity of the CD47 modified and 
corresponding control sensors over naturally occurring electroactive interference species (ascorbic 
acid and uric acid), was evaluated by injecting near maximum in vivo concentrations of these 
interference species into the in vitro cell during the glucose calibrations (from 1.0 – 20.0 mM).  
The % error for these sensors was calculated by dividing the current response from an injection of 
interference species (0.5 mM for ascorbic acid and 0.33mM for uric acid20 by the current signal 
recorded for 5.0 mM glucose.  A threshold was established to determine effective selectivity.  The 
threshold was defined as the current from a specific interference species should not exceed 5% of 
the current response from a 5.0 mM glucose.  The selectivity test was repeated and monitored over 
a 14-d period to evaluate the stability of the selectivity layers.  Comparisons in stability were 
evaluated between the CD47 modified sensors and the control group of sensors, which were kept 
in storage in the University of Michigan Chemistry Department and not CD47 functionalized. 
3.3  Results and Discussion 
3.3.1  Assessment of Glucose Oxidase Activity of CD47 Modified Sensors Before and After CD47 
Functionalization 
As shown in Figure 3.6 (a-d), four CD47 glucose sensors that were successfully modified with 
recombinant CD47 protein retained their glucose linearity, and therefore, their glucose oxidase 
activity throughout the complete functionalization procedure (Section 3.2.4).  Dr. Stachelek 
reported that via fluorescence intensity assay, a coating of 85.0 ng/cm2 of CD47 had been 
successfully deposited onto the glucose sensor surfaces, indicating that E2As is an acceptable 
candidate polymeric surface material for CD47 modification. The variations in the slopes of the 
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different sensors is primarily due to variations in the thickness of the outer polyurethane coating, 
which is difficult to control using the manual loop casting method employed.  
 
Figure 3.6.  Glucose sensor calibration data prior to and after CD47 surface functionalization. 
Figure 3.7 shows the same glucose calibrations performed on control glucose sensors that did 
not undergo the CD47 surface functionalization.  The preservation of linearity and glucose oxidase 
activity indicates that any perceived change in glucose oxidase activity in the CD47 functionalized 
sensors was not due to age of the sensors. 
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Figure 3.7.  Glucose sensor calibration of the control sensors, which were not CD47 
functionalized, but were re-calibrated simultaneously when the modified sensors were received. 
  
Figure 3.8 shows a comparison of selectivity over electroactive interference species before and 
after CD47 functionalization.  The lifetime of the CD47 sensors was much longer than the sensors 
evaluated in Chapter 2 (due to shipment and processing at CHOP), and thus the observed higher 
standard deviations for selectivity between the sensors may indicate that a combination of extended 
lifetime and the functionalization procedure did partially exhaust the effectiveness of the annealed 
Nafion layer of these sensors; however, the average interference response is still well within the 
5% threshold deemed acceptable for blood glucose sensors. 
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Figure 3.8.  Comparison between CD47 functionalized sensors and control sensors of selectivity 
against negative electroactive interference species (ascorbic and uric acids).  The upper plot 
displays selectivity of the sensor against 0.5 mM ascorbic, acid and the lower plot shows selectivity 
over 0.44 mM uric acid.  The steady-state current resulting from these interference species should 
not exceed 5% of the steady-state current response from 5.0 mM glucose (blue line).  
 
3.3.2  Discussion and Future Combination of In Vivo Studies  
Dr. Stanley Stachelek and coworkers at CHOP confirmed the density of recombinant protein 
attachment was determined by conjugation with a FITC-tagged antibody specific for human CD47 
via BD Biosciences (Franklin Lakes, NJ)2.  The next logical step will be to determine whether 
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immobilized CD47 confers sufficient hemocompatibility to enable the glucose sensors not to 
activate the coagulation cascade when tested in vivo.  Studies to conduct such studies are being 
planned.  Another important question to answer is whether immobilized CD47 provides equivalent 
anti-platelet activity as sensors prepared only with nitric oxide releasing capability (see Chapter 
4), or might sensors prepared with a combination of both immobilized CD47 and NO release be 
the most desirable approach to enhancing biocompatibility?  To potentially pursue this approach, 
the nitric oxide releasing polymeric coating would need to be added first as an inner layer and then 
the CD47 could be functionalized on the outermost surface of a thin additional layer of  
polyurethane.  Since NO is readily permeable through polyurethanes adding this layer should have 
little effect on the NO release flux of such a sensing device. 
3.4  Conclusions 
Intravenous needle-type glucose sensors coated with the E2As Elast-Eon polyurethane can be 
successfully functionalized on their outer surface with recombinant CD47 protein domains through 
a photopolymerization procedure to thiolate the polymer surface.  This immobilization process, 
which takes approximately 1 h to form thiol reactive groups on the surface followed by 14 h 
incubation time at 4°C with the poly-lysine recombinant CD472, does not adversely influence the 
glucose response properties of such sensors.  Indeed, sensors retain their linear response range and 
glucose oxidase activity after the surface functionalization procedure, and retain an acceptable 
level of selectivity over electroactive interference species through the use of an annealed Nafion 
inner layer. 
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CHAPTER 4 
IMPROVED THROMBORESISTANCE AND ANALYTICAL PERFORMANCE OF 
INTRAVASCULAR AMPEROMETRIC GLUCOSE SENSORS USING NITRIC OXIDE 
RELEASE COATINGS WITH PRELIMINARY IN VIVO EXPERIMENTS 
4.1  Introduction 
Accurate monitoring and control of blood glucose play critical roles in the treatment of patients 
with diabetes millitus.  Benchtop point-of-care devices are the current standard for many hospitals 
and medical care facilities, and finger prick glucometers are widely used for personal and home 
glucose measurements.  While these devices yield discrete blood glucose values, trends of rapidly 
increasing/decreasing glucose concentrations often go unobserved when such devices are used.  
Some commercially available systems provide continuous glucose monitoring of interstitial fluid 
using implanted electrochemical sensors.  However, due to the ~10-15 minute lag time between 
changes in blood glucose concentration and changes in interstitial fluid glucose,1 in practice these 
devices can only supplement, rather than fully replace, discrete blood measurements.  
 
*Note: Sections from this chapter are adapted from the following publication by this Ph.D. 
candidate: A. K Wolf, Y. Qin, T. C. Major, M. E. Meyerhoff, “Improved Thromboresistance and 
Analytical Performance of Intravascular Amperometric Glucose Sensors using Optimized Nitric 
Oxide Release Coatings,” Chinese Chemical Letters, (2015) Volume 26, pages 464-468. 
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Intravenous amperometric glucose sensors may provide a better alternative platform for 
continuous blood glucose measurements, especially within a hospital environment.  Such 
monitoring could not only decrease potential complications for diabetic patients, but also offers 
better outcomes for non-diabetic patients, both benefiting from tight glycemic control.  Indeed, 
tight glycemic control is a requirement for many patients in intensive care units (ICUs) to achieve 
targeted treatment and better patient outcomes.  The amperometric glucose sensors described in 
this work are designed to be implanted intravenously in critical care patients through existing IV 
port access or inserted into a catheter.  Continuous measurement from these devices would provide 
medical staff with the ability to see trends in rising and falling blood glucose, allowing them to 
select better treatment options.  Miniaturized electrochemical blood glucose sensors have been 
previously reported in literature, and have been developed into commercialized products for 
measurement in subcutaneous interstitial/brain fluid matrices; however, these sensors can quickly 
lose analytical accuracy due to thrombus formation on their surfaces when placed within the 
bloodstream of hospitalized patients.2,3  Via the formation of thrombus with encapsulated platelets, 
the local glucose concentration near the surface of the sensor can be reduced by metabolic activity 
of platelets and other trapped cells and, therefore, the sensor reads a false glucose value compared 
to the level of glucose within the plasma phase of the blood.  The well-known antithrombotic and 
anti-inflammatory properties of nitric oxide (NO) provide a useful method of potentially enhancing 
the hemocompatibility of a blood contacting surface.  Incorporating NO releasing donor molecules 
into a sensor’s outer polymeric coatings allows it to mimic the functions of endothelial cells lining 
the inner walls of all blood vessels, which endogenously release NO at localized fluxes of 0.5 – 
4.0 x10-10 mol cm-2 min-1.4  This approach has previously been shown to reduce clot formation on 
the surface of intravenous glucose sensors and preserve their in vivo performance.5,6  Herein we 
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extend this earlier work by further optimizing the NO release formulation and the outer glucose 
restriction layer used to prepare such devices to achieve more optimal linearity and in vivo 
performance. 
 
4.2  Experimental 
4.2.1  Materials 
Glucose oxidase (Type VII, from Aspergillus niger), d(+)-glucose, glutaraldehyde, bovine 
serum albumin (BSA), fetal bovine serum (filtered, sterilized), hemoglobin(lyophilized, from 
bovine blood), iron (III) chloride (FeCl3), 37% hydrochloric acid (HCl), Nafion (5 wt% solution 
in lower aliphatic alcohols/H2O mixture), 1,3-diaminobenzene, resorcinol, tetrahydrofuran (THF), 
N,N’-dibutyl-1,6-hexanediamine (DBHD) were all obtained from Sigma-Aldrich (St. Louis, MO).  
Sodium phosphate dibasic heptahydrate (Na2HPO4 · 7H2O), sodium phosphate monobasic 
monohydrate (NaH2PO4 · H2O) were purchased from Amresco, Inc. (Solon, OH).  Sodium chloride 
(NaCl) is a product of Research Products International Corp. (Mt. Prospect, IL).  Potassium 
chloride is from Fisher Scientific (Pittsburgh, PA).  Teflon-coated platinum/iridium and silver 
wires are products of A-M Systems (Sequim, WA).  E2As Elast-Eon polyurethane was a gift from 
Aortech Biomaterials (Weybridge, Surrey, UK).  Diazeniumdiolated DBHD (DBHD/N2O2) was 
synthesized by treating DBHD with 80 psi nitric oxide (NO) gas purchased from Cryogenic Gases 
(Detroit, MI) at room temperature for 24 h, as previously described.5  Accu-Chek SmartView 
testing strips and the associated Accu-Chek Nano hand-held glucose meter are commercially 
available products from Roche Diagnostics (Risch-Rotkreuz, Switzerland) 
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4.2.2  Sensor Fabrication 
Glucose sensor design (see Fig. 4.1) was based on previous configurations5-8 by first cutting a 
1-mm length cavity in the Teflon coating of a platinum/iridium wire (outer diameter = 0.2 mm).  
A Nafion coating was then applied to the cavity, and then the wires that feature an annealed Nafion 
inner selective membrane were placed in a Fisher Scientific Isotemp oven set to 170°C for 1.5 h 
and then gradually cooled to 35°C to enhance sensor selectivity against negatively-charged 
electroactive interference species, such as ascorbic and uric acid, as described in Section 2.2.2 of 
this thesis.  Non-annealed sensors were dried at 37.5°C, rather than annealed.  Then, via a CV 
electropolymerization process (cycling voltage between 0 and +0.830 V at 0.002 V/s for 18 h) a 
layer of polymerized resorcinol and m-phenylenediamine6,9 was applied to the cavity to help 
further reject neutral electroactive interference species, such as acetaminophen, from reaching the 
inner Pt/Ir surface.  A silver/silver chloride (Ag/AgCl) wire electrode was tightly wrapped around 
the sensor to serve as an electrochemical reference, and heat-shrinkable polyester tubing was 
applied to secure the reference wire in place.  Glucose oxidase was then immobilized within the 
cavity using glutaraldehyde.  An outer polymer layer was then applied to the sensor’s surface using 
a wire loop: a 2% (wt/vol) Elast-Eon E2As polyurethane in THF was applied with a wire loop as 
a top coat to modulate the NO release and also control the sensor’s linear detection range for 
glucose by restricting glucose diffusion into the immobilized enzyme layer.  E2As polyurethane 
was chosen for these studies since it had been previously used with positive success as an NO 
release coating to prevent platelet activation and clotting within a rabbit model for extracorporeal 
circulation.10  Additional outer layers were then applied to the sensor’s surface using a wire loop: 
an ester-capped polylactic acid layer containing diazeniumdiolated dibutylhexyldiamine (2:1, 
wt:wt) (Fig. 4.1c) was applied to provide the sensor NO releasing behavior, and then an additional 
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2% (wt/vol) Elast-Eon E2As polyurethane in THF (Fig. 4.1b) was applied as a top coat to modulate 
the NO release and also control the sensor’s linear detection range for glucose by restricting 
glucose diffusion into the immobilized enzyme layer.  A diagram of the fully-assembled sensor is 
shown in Fig. 4.1a.  Control sensors were prepared using a similar procedure except that no 
diazeniumdiolated dibutylhexyldiamine was doped within the PLA coating. 
 
Figure 4.1.  (a) Needle/catheter type glucose sensor design; (b) E2As Elast-Eon polyurethane used 
for the sensor outer layer; (c) Lipophilic diazeniumdiolated dibutylhexyldiamine and the proton-
driven mechanism for nitric oxide release. 
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4.2.3  In Vitro Analytical Performance of Annealed Glucose Sensors 
Glucose sensors were calibrated using 4-channel BioStat potentiostats (ESA Biosciences Inc., 
Chelmsford, MA).  The potential applied to the inner Pt/Ir wire was +0.600 V vs. Ag/AgCl 
reference in a 0.1 M phosphate buffered saline (PBS), pH 7.4, test solution at 37.5°C.  In vitro 
glucose calibrations were conducted in both phosphate buffered saline (PBS) and fetal bovine 
serum, as the bovine serum was identified as an intermediate matrix between buffered saline 
solution and the whole blood of an in vitro experiment.  Total glucose concentration of the serum 
was assessed using a commercial AccuChek SmartView glucometer. 
4.2.4  In Vitro Assessment of NO Release 
Nitric oxide released from these glucose sensors was monitored via chemiluminescence using 
a Sievers Nitric Oxide Analyzer (NOA) 280i (Boulder, CO).  Measurement occurred when the 
sensors were immersed in 0.1 M PBS, pH 7.4, at 37.5°C and the NO release data were collected.  
Long-term NO release was monitored by collecting daily release measurements to ensure that flux 
(based on surface area) was above the 0.5 x 10-10 mol cm-2 min-1 minimum threshold for 
endogenous NO release from endothelial cells.4 
4.2.5  In Vivo Protocol for Evaluation of Sensor Performance During 7h Implantation Within 
Rabbit Veins 
In vivo 7h rabbit experiments were conducted through the assistance of surgical specialist Terry 
Major (a member of the Dr. Robert H. Bartlett lab in the University of Michigan Department of 
Surgery).  The rabbits were anesthetized for the duration of the procedure.  Briefly, three sensors 
(typically two NO release, and one non-NO release control) for each rabbit were inserted into the 
two jugular veins and one femoral vein, and sutured in place.  To assess the glucose calibration 
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accuracy, the discrete venous blood glucose values, measured by an ALB-800 Flex Radiometer 
blood gas analyzer every 30 min, were recorded and compared with the continuous measurements 
provided by the sensors.  Several bolus injections of 50% dextrose solution were given 
intravenously to modulate the rabbit’s venous glucose concentration.  At the conclusion of the 
experiment, the sensors were explanted and photographed to examine the extent of surface clotting 
that had developed.  Post-experimental glucose calibrations (in 0.1M PBS and/or bovine serum) 
as well as post-experimental NO release measurements were also conducted.  A continuous time-
trace of the sensor’s measurements is reported, based on both a one-point calibration from a 
discrete Radiometer measurement made early in the experiment as well as an in vitro calibration 
curve conducted in bovine serum prior to the experiment. 
4.2.6  In Vivo Protocol for Evaluation of Sensor Performance During 20h Implantation Within 
Porcine Blood Vessels 
In vivo 20 h porcine experiments were conducted through the assistance of surgical specialists 
Drs. Megan Coughlin, Alvaro Rojas Pena, and Joseph Church and animal specialists Salvatore 
Aiello and Elena Perkins (members of the Dr. Robert H. Bartlett lab in the University of 
Michigan’s Department of Surgery).  The pigs were anesthetized for the duration of the procedure.  
Briefly, the NO releasing sensors corresponding to Figures 4.6, 4.7 and 4.8 were inserted into the 
jugular vein, and sutured in place.  (In this case, the femoral venous access sites for these 
experiments were used for testing a colleague’s intravenous glucose sensors simultaneously.)  To 
assess the glucose calibration accuracy, the discrete venous blood glucose values, taken by an 
ALB-800 Flex Radiometer blood gas analyzer each hour, were recorded and compared with the 
continuous measurements provided by the sensors.  Several bolus injections of 50% dextrose 
solution were given intravenously to modulate the rabbit’s venous glucose concentration.  At the 
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conclusion of the experiment, the sensors were explanted and photographed to examine the extent 
of surface clotting that had developed.  Post-experimental glucose calibrations (in 0.1M PBS 
and/or bovine serum) as well as post-experimental NO release measurements were also conducted.  
A continuous time-trace of the sensor’s measurements is reported, based on a two-point calibration 
from discrete in vitro Radiometer measurements made early in time after the start of each animal 
experiment. 
4.2.7  Glucose Sensor Surface Investigation with SEM and Diffusion Cell Assessment of Membrane 
Potential 
To investigate the outer polyurethane layers’ topography as well as the structure of the NO 
releasing PLGA/DBHD/N2O2 layer, SEM images were taken of the surface profile and cross-
sectional areas of sample glucose sensors on an Amray 1910 FEG-SEM.  Thicker versions of the 
E2As Elast-Eon polyurethane and a sandwich membrane composed of a layer of PLGA and 
DBHD/N2O2 between two layers of E2As Elast-Eon were cast and placed into glass diffusion cells.  
In one type of experiment, the both halves of the diffusion cell were filled with 0.1 M PBS with a 
membrane clamped into place between them, and a commercial reference electrode was placed on 
each side.  When one side was replaced with bovine serum, any potential change was recorded in 
order to assess whether an unintended potential developed across the polyurethane membrane 
when the aqueous environments on each side were asymmetrical.  A Lawson Labs multi-channel 
potentiostat was used to measure the open circuit potentials of each electrode. 
In a second type of experiment, both halves of the diffusion cell were filled with 0.1 M PBS 
with a membrane clamped into place between them, and a fabricated glucose sensor (described in 
Chapter 2) was placed into one half-cell.  A high concentration of glucose was injected into the 
80 
 
half-cell not containing the glucose sensor and the current reading from the sensor was monitored 
with a BioStat to detect glucose able to diffuse across the thicker membrane.  The solutions in each 
section cell were well stirred. 
4.2.8  In Vitro Investigations of Intravenous Medications on Glucose Oxidase Activity 
Based on poor analytical performance of sensors during the 20 h porcine experiments, several 
additional benchtop measurements were conducted to examine potential interferences from 
intravenous drugs administered to the pig during the longer-term experiments.  These drugs serve 
as anesthetics or pressors to maintain the animal’s blood pressure.  Injections of dopamine, 
vercuronium bromide, heparin, and epinephrine (each separately) were made into cells containing 
10 mM glucose to check for any major changes in sensor output current, either as electroactive 
species or as an inhibitor of glucose oxidase activity.  An experiment was also conducted by 
replacing a 0.1 M PBS solution containing NO releasing sensors (without glucose oxidase) with 
concentrated oxyhemoglobin to examine if the oxyhemoglobin scavenged an appreciable amount 
of local NO, causing any background current due to NO oxidation at the surface of the inner Pt 
working electrode to decrease. 
4.3  Results and Discussion 
4.3.1  In Vivo Evaluation of Sensor Performance During 7 h Implantation Within Rabbit Veins 
NO releasing glucose sensors were soaked in phosphate buffered saline (PBS) or bovine serum 
at physiological conditions (pH 7.4, 37.5oC) to hydrate the polyurethane layer for restricted 
glucose diffusion and to activate the NO release with protons within the PLA layer.  The PLA 
controls the local pH of the NO releasing layer by supplying protons as it slowly hydrolyzes.  
Ideally performing sensors release NO at a stable flux at physiological levels found for endothelial 
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cells (0.5 – 4.0  10-10 mol cm-2 min-1) for the duration of the sensor’s functional lifetime.  Nitric 
oxide release from the surface of the sensors was measured by chemiluminescence using a Sievers 
Nitric Oxide Analyzer (NOA) 300i.  The NO release profile over 7 d of the optimized sensors used 
for the in vivo experiment can be seen in Fig. 4.2a.  The sensors maintained NO release above 0.5 
x 10-10 mol cm-2 min-1 over this period while stored in bovine serum solution (containing glucose 
at physiological levels).  Without the addition of PLA, the NO release profile would exhibit an 
initial burst followed by a much sharper daily decay.  As indicated in Fig. 4.1c, the NO release 
mechanism from diazeniumdiolated dibutylhexyldiamine is dependent upon a steady supply of 
protons.  In our previously published in vivo glucose sensor experiments, a 50:50, acid-capped 
poly(lactic-co-glycolic acid) (PLGA) was used to formulate the NO release layer to control local 
pH at the sensor surface.  The innate acid-terminated polymer chains of this material coupled with 
the co-polymer structure yield relatively rapid hydrolysis rates; thus, the NO release profile based 
on PLGA begins with a large burst of NO on day 1 with a characteristic decay over subsequent 
days.  In contrast, the PLA used in the studies reported herein has ester-capped end groups, which 
slows the hydrolysis rate, and therefore provides a more stable NO release profile for the duration 
of testing.  This ensures that NO release will remain greater than 0.5  10-10 mol cm-2 min-1 until 
after the 7th day of sensor lifetime. 
E2As Elast-Eon, a polymer composed of a mixed soft segment of poly(-dimethylsiloxane) and 
poly(hexamethylene oxide) with a methylene diphenyl isocyanate (MDI) hard segment, was used 
as the outermost coatings in the fabrication of the glucose sensors because it has been reported to 
exhibit excellent intrinsic biocompatibility and biostability, with low levels of blood protein 
adhesion.11,12  Since the inherent hemocompatibility of this material should enhance the overall 
thromboresistance properties from the NO release devices, E2As was selected as a replacement 
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for PurSil Thermoplastic silicone polyether used in our previous in vivo glucose sensor designs.6  
In benchtop studies, the E2As coated sensors displayed the desired control over the linear glucose 
detection range (slowing glucose diffusion to enzyme layer so sensor is not limited by oxygen 
levels); the NO release through this layer was also quite acceptable for this in vivo study.  The 
linear range for amperometric glucose response of the NO release sensors was also measured in 
two types of solutions (PBS and bovine serum) in vitro before and after the in vivo implantation 
to evaluate their performance and recovery.  Ideally, a sensor should have linear response not only 
within the standard resting blood glucose range of 4.4 – 6.6 mM, but it should also provide accurate 
measurements within the hypoglycemic and hyperglycemic ranges (1.0 -20.0 mM).  The sensor 
should also be selective over other electroactive species present in blood that interfere with the 
electrochemical oxidation of hydrogen peroxide at the sensor’s operating potential of +0.600 V 
(vs. Ag/AgCl).  The glucose calibration curves for a representative sensor tested in vitro within 
both PBS and bovine serum (Fig. 2b) demonstrate that the sensor has a similar linear range in both 
environments, although a higher calibration intercept and decreased sensitivity are observed in 
serum, which may result from the presence of additional unknown interfering species within that 
commercial serum matrix.  Response times for sensors intended for continuous monitoring should 
also be as short as possible so that they quickly react to rapid blood glucose concentration changes.  
Accordingly, the typical response times for the sensors employed in the in vitro serum calibration 
experiment shown in Fig. 4.2b were 5 min (with response time defined as the time required for the 
signal to achieve 95% of its final steady-state amperometric value after change in glucose 
concentration). 
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Figure 4.2. (a) Nitric oxide release fluxes of sensors stored in bovine serum at 37.5oC for three 
days prior to day 1 testing, and day 7 measurements were conducted after in vivo implantation; (b) 
Calibration curves of representative sensor in both PBS and bovine serum at 37.5oC before in vivo 
implantation. 
 
When implanted into rabbit jugular veins, the glucose sensors were used to measure the in vivo 
blood glucose level and generate an amperometric time trace (Fig. 4.3a).  When a bolus of 50% 
dextrose solution was given intravenously to modulate the rabbit’s venous glucose concentration, 
the NO releasing sensor responded to the resulting change in blood glucose with a proportional 
increase in anodic current.  Also, as observed in Fig.4.3b, after the 7 h in vivo experiment the NO 
releasing sensor does not develop significant clotting on its surface; hence, when the sensor’s 
surface is in direct contact with the blood, and the observed current will remain proportional to the 
true blood glucose value.  In contrast, the control sensor without NO release quickly developed a 
surface clot, as shown in Fig. 4.3b.  The contrast between the clotting patterns of the control and 
NO release sensors is very similar to results obtained from previous glucose sensors that were 
evaluated in vivo via rabbit studies.6  Therefore, this behavior is representative of the expected 
clotting that will be observed when additional sensors with the optimized outer layers are tested 
within future in vivo animal studies.  The cells within the clot (e.g., platelets) consume glucose in 
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the localized sensing area and this also creates an additional diffusion barrier, resulting in very low 
currents for the control sensor when placed in vivo.  It should be noted that due to anesthesia, the 
rabbit’s glucose levels start at hyperglycemic levels (13.8 mM), and then drop with time until 
dextrose is infused.  
 
Figure 4.3. (a) Raw current time trace of in vivo implanted sensors. Two injections of 50% 
dextrose were given to modulate the blood glucose of the rabbit; (b) Photos of the control (top) 
and NO release (bottom) glucose sensors after the in vivo experiment.  The portions of the sensors 
to the left of the dashed lines were actually inside the veins. 
 
To assess the glucose calibration accuracy, the discrete venous blood glucose values, taken 
with the ALB-800 Flex Radiometer blood gas analyzer, were compared with the continuous 
measurements provided by the sensors.  Both a one-point calibration based upon the venous blood 
glucose at the 1 h time-point and the in vitro calibration of the NO releasing sensor in bovine serum 
were used to convert the raw current values to corresponding glucose concentrations.  In Fig. 4.4, 
the discrete venous blood glucose values are compared with the continuous glucose measurements, 
converted by a one-point calibration and the in vitro bovine serum calibration for the NO releasing 
sensor and by a one-point calibration for the control sensor.  The NO releasing sensor quickly 
responds when a bolus of 50% dextrose is given intravenously, and the calibrated glucose values 
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more closely match those of the blood gas analyzer than those of the control sensor.  The delay in 
response time to the dextrose boluses and the deviations from the venous blood glucose 
concentration by the control sensor are likely due to the heavy surface clot formation (Fig. 3b). 
 
Figure 4.4. Comparison of glucose concentration values obtained from benchtop blood gas 
analyzer and the converted current values measured by the continuous sensor.  One conversion of 
current to glucose concentration (mM) was made with the calibration curve in bovine serum (Fig. 
4.2); the other conversion was a one point calibration taken at the 1 h time point. 
 
Thus, NO release provides the sensor with resistance to in vivo thrombosis, allowing the sensor 
to maintain continuous analytical functionality and measurement accuracy for the duration of its 
implantation.  The one-point ex-vivo Radiometer instrument blood gas calibration and the bovine 
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serum calibration both yielded similar values when used to convert the raw current values obtained 
from the NO-releasing sensor. 
4.3.2  In Vivo Evaluation of Sensor Performance During 20 h Implantation Within Porcine Blood 
Vessels 
In a similar manner as the NO release sensors fabricated for the 7 h rabbit studies, sensors 
intended for porcine implantation were first soaked in phosphate buffered saline (PBS) or bovine 
serum at physiological conditions (pH 7.4, 37.5oC) to hydrate the polyurethane layer for restricted 
glucose diffusion and activate the NO release.  Previously reported in vivo data for glucose sensors 
did not show dextrose modulation on the sensor’s continuous time trace plot.13  The 20 h porcine 
experiment is more than twice the duration of previous in vivo data collection from intravenous 
glucose sensors.  Other long term glucose implantation involves subcutaneous placement and an 
initial adjustment time before data collection to account for decreased vascularization and foreign 
body encapsulation at the implant site.  Several small design modifications were made to better 
suit them for the extended implantation time, including an extra 5.0 µL layer of NO releasing layer 
(PLGA/ DBHD/N2O2) applied specifically over the cross-linked glucose oxidase cavity and 
Ag/AgCl reference wire coil.  Early experiments showed that even though NO release prevented 
major thrombosis on the sensor surface, minor clotting could occur specifically on top of the 
enzyme cavity, perhaps where local (surface) NO concentration was the smallest owing to 
electrochemical NO oxidation adjacent to the enzyme layer.  In addition, the glucose sensor’s total 
length was extended from 12 cm to 22 cm to accommodate placement in the larger animal and 
ensure that electrode leads could be properly attached to the potentiostat.  Figure 4.5 shows a 
comparison of glucose calibration for two NO releasing sensors conducted in 0.1M PBS versus 
bovine serum for the porcine sensors. 
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Figure 4.5.  Respective glucose calibrations in 0.1 M PBS and bovine serum for two NO releasing 
glucose sensors (a & b) that were evaluated for in vivo analytical performance in Fig 4.6.  The 
slope from the serum calibration and an average of the intercepts from the PBS and serum 
calibrations were used to convert raw current from the sensors into glucose concentration values 
in Fig. 4.6a. 
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Figure 4.6(a-c).  In vivo intravenous glucose measurement time-traces from two NO releasing 
glucose sensors during porcine implantation and three methods of data interpretation: (a) pre-
implantation serum calibration (see Fig. 4.5), (b) a 1-point calibration from a Radiometer blood 
glucose value taken at 2.6 h, and (c) a 2-point calibration from Radiometer blood glucose values 
taken at 6.8 and 8.6 h.  The discrete hourly Radiometer analyzer glucose values are plotted as 
square markers. 
 
 
Figure 4.7.  Explanted NO releasing glucose sensors from the in vivo porcine measurements taken 
in Figure 4.6.  Minimal clotting is observed on the sensor surface, except where the close proximity 
placement of two sensors formed a “bridge clot”. 
Glucose oxidase cavity 
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During the 20 h of intravenous porcine blood glucose measurements (Fig. 4.6a-c), the NO 
releasing glucose sensors tracked the rising and falling patterns of the blood glucose levels as 50% 
dextrose bolus injections were administered.  Blood glucose was allowed to stabilize (typically at 
7-8 mM) before any dextrose was given.  Unfortunately, the pig in this experiment died 
unexpectedly from low blood pressure before the 20 h duration was complete.  The linear equation 
obtained from the calibration in serum (Fig 4.5b), which was used to convert the raw sensor current 
values into glucose concentrations in Figure 4.6a, did not yield accurate glucose values within an 
acceptable error of those measured discretely at hourly time points.  The predicted glucose values 
based on the serum calibration have a large error in comparison to the Radiometer values, 
indicating that the slope and intercept of the sensor in the porcine vein are very different from 
those measured in serum.  If the sensors cannot easily be calibration in serum prior to implantation, 
the next best model would be a one-point calibration from a Radiometer value early in the 
experiment.  The Radiometer blood glucose value from 2.6 h into the experiment was used to 
convert the raw sensor current into glucose concentration values in Figure 4.5b.  Converted glucose 
concentration values close to this one-point calibration point may have less error from the true 
glucose concentration values, but values at the end of the experiment have a greater degree of error.  
This could indicate drifting behavior in the sensor sensitivity during extended 20 h in vivo which 
is not observed in vitro or in the shorter 7 h in vivo rabbits. 
Thus, a two-point calibration from discrete blood glucose values taken at the 6.1 h and 8.6 h 
time points provided the best conversion of raw sensor current values into accurate venous glucose 
concentrations in Figure 4.6c.  Measurements early in the in vivo study are the most preferred to 
use for such an in vivo calibration approach, since this would allow the sensor to be calibrated 
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quickly after implantation, and hopefully this calibration would remain accurate for the remainder 
of the implantation period.  Ideally, all discrete points should fit closely to the lines consisting of 
the continuous measurements within the bloodstream.  However, experimentally, calibrations 
conducted from discrete blood measurements taken in between the 6-9 h time period after 
implantation yielded the most accurate blood glucose values from the sensor.  The data from the 
sensor predicts glucose values higher than those measured by the Radiometer analyzer, especially 
in the final hours of the experiment.  This could indicate drifting behavior of the sensors between 
the time the two-point calibrations were taken and the measurements at the end of the experiment.  
This behavior was not observed in the shorter rabbit experiments, and it was not possible to 
conduct longer-term implantation in anesthetized rabbits for durations longer than 7 h; therefore, 
it was not clear if this behavior arose from differences in physiology between rabbits and pigs, 
differences in anesthesia protocol/intravenous drugs administered specifically to the pig, or it was 
simply a function of the longer duration of the animal experiment.  When the sensors were 
explanted from the pig vein, they were examined for surface clotting as observed in Figure 4.7, 
very little surface clotting was observed, likely a result from both small surface area and active 
NO release chemistry.  Since these two sensors were placed in the same angiocatheter for 
implantation within the same vein, a small “bridge clot” developed between the two sensors with 
reduced blood flow between the sensors due to their close proximity. 
Results from an additional in vivo experiment in a pig are shown in Figure 4.8.  With a two-
point calibration (from blood-gas measurements taken at 6.1 h and 9.0 h), the sensor tracks the 
increasing and decreasing blood glucose values during the modulations by dextrose injections.  
From hour 4.0 until 15.0, the values from the glucose sensor closely match the discrete in vitro 
Radiometer glucose concentrations, but somewhat higher glucose concentrations than expected 
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are observed from the implanted sensor during the final hours of implantation.  Although the 
analytical performance of these NO release IV glucose sensors still require further efforts to 
improve analytical accuracy, these experiments are the first reported use of NO release intravenous 
glucose sensors for continuous in vivo measurement exceeding the previous 7 h time period in 
rabbits.  
 
Figure 4.8.  In vivo intravenous glucose measurement time-trace from an NO releasing glucose 
sensors during porcine implantation.  A two-point calibration from the discrete bench-top blood-
gas analyzer was used to convert raw current measurements from the sensor into blood glucose 
concentration values.  The discrete hourly blood-gas analyzer glucose values are plotted as squares.  
The continuous measurements from the sensor best fit the discrete measurements from the 
Radiometer blood gas analyzer in the middle implantation, from 4-15 h. 
 
Further in vitro studies (see Sections 4.3.3 and 4.3.4, below), were conducted to investigate 
changes in the calibration background (hemoglobin scavenging of NO), or if intravenous drugs 
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administered during the pig experiments could influence the glucose sensor sensitivity, that could 
account for this discrepancy in sensor behavior.  In other words, it is important to understand what 
causes the large change in sensitivity of the NO release glucose sensors when they are implanted 
in pig blood vessels, which resulted in the need to wait 6-9 h periods to calibrate the sensors based 
on two separate in vitro blood glucose measurements. 
4.3.3  Diffusion Cell Assessment of Membrane Potential and Glucose Sensor Surface Investigation 
with SEM 
In an effort to determine if an additional potential develops across the outer membrane of the 
glucose sensor when in environments different than 0.1 M PBS (i.e., such a membrane potential 
could change the applied voltage to the Pt electrode, leading to decreased sensitivity to hydrogen 
peroxide), a series of diffusion cell experiments were designed.  First, each side of the diffusion 
cell contained 0.1 M PBS and a reference electrode measured the open circuit potential (OCP) 
across the membrane (Fig. 4.9a).  Separating the two cells was a membrane either of E2As Elast-
Eon polyurethane, or a sandwich membrane composed of a layer of PLA/DBHD/N2O2 between 
two layers of E2As.  Then the solution on one side would be replaced with bovine serum (Fig 4.9b) 
to see if a potential developed across the membrane.  If a large potential was observed immediately, 
or developed over time, it could indicate that a membrane potential was causing only part of the 
+0.600V vs. Ag/AgCl potential to be correctly applied to the inner Pt electrode surface.  A 
decreased applied potential would result in a smaller, possibly drifting, current response and 
reduced analytical accuracy.   
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Figure 4.9.   Diffusion cell experiment to detect a membrane potential developing across an E2As 
membrane  In (a) both sides of the diffusion cell contain 0.1 M PBS and a commercial reference 
electrode  In (b) the left side solution has been changed to bovine serum. 
 
Figure 4.10 shows the difference in OCP between the two reference electrodes when the 
separating membrane is pure E2As.  The difference between the initial and the new OCP was  -
0.95 mV after the addition of the bovine serum, indicating that E2As alone, as a homogeneous 
membrane did not give rise to a significant membrane potential when it came into contact with a 
serum solution. 
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Figure 4.10.  Open circuit potential difference between the two sides of the diffusion cell separated 
by a membrane of pure E2As when both sides have a symmetrical configuration with 0.1 M PBS 
filling solution versus the OCP measured when one side’s solution was changed to bovine serum. 
 
Figure 4.11.  Open circuit potential difference between the sides of the diffusion cell separated by 
a sandwich membrane of PLA/DBHD/N2O2 between two layers of E2As when both sides have a 
symmetrical configuration with 0.1 M PBS filling solution versus the OCP measured when one 
side’s solution was changed to bovine serum. 
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In Figure 4.11 it can be seen that a sandwich membrane, designed to better mimic the outer 
layers found on the glucose sensors gives rise to a largeer potential difference when one side of 
the diffusion cell is filled with bovine serum.  A difference in open circuit potential of -5.0 mV, 
which develeoped from the switch from PBS to bovine serum is larger than one observed when 
using a homogeneous E2As membrane, but this small 5.0 mV decrease in applied potential would 
still not account for the magnitude of calibration drift observed in the in vivo experiments. 
To investigate the bulk diffusion properties of the glucose sensors’ outer layers that restrict 
glucose diffusion and thereby give the sensor linear response, another diffusion cell experiment 
was conducted.  In this case, a functioning glucose sensor was placed into one side of the diffusion 
cell (containing 0.1 M PBS) and a 1.0 mL of 2.0 M glucose was injected into the PBS on the 
opposite side.  A quick response from the sensor would indicate rapid diffusion, likely through 
larger diffusion channels or membrane pores.  In contrast,  a slow sensor response would instead 
indicate very small channels or pores.  However, no significant response was recorded from the 
glucose sensor, even after measuring for >1 d, giving evidence to the hypothesis that small pinholes 
in the very thin membranes coating the glucose sensors are likely responsible for glucose diffusion 
restriction, providing the sensors with their linear response function to glucose over an extended 
concentration range.   
A series of SEM images were taken of the exterior E2As surface as well cross-sectional images 
of the sensor to identify surface pinholes (Fig 4.12a) and the structure of the PLA/DBHD/N2O2 
releasing layer (4.12b).  Figure 4.12a highlights some of the small 1-µm size pinholes found in the 
E2As surfaces of glucose sensors.  Pinholes of this size would account for restricted diffusion of 
glucose into the glucose oxidase layer, giving the sensors linear response.  Distribution of these 
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pinholes over a given area could also help account for variations between individual sensors when 
they are assembled and fabricated by hand.  The SEM in Figure 4.12b is one taken from a cross-
section of an NO releasing glucose sensor.  The outer E2As membrane is quite smooth, other than 
the presence of pinholes that link to the NO releasing layer below it, but the structure of the PLA/ 
DBHD/N2O2 layer has a porous nature.  Given that the PLA/ DBHD/N2O2 layer is approximately 
10x the thickness of the E2As layer, one can explain why glucose sensors with thick NO releasing 
layers (to maximize NO release duration) have longer response times (to achieve steady-state 
current values) than sensors fabricated with thinner NO releasing layers or outer layers of only 
E2As polyurethane. 
 
Figure 4.12.  SEM images of glucose sensor outer layers showing (a) pinholes in the 5 µm thick 
E2As outermost top coat and (b) the porous structure of the PLA & DBHD/N2O2 layer responsible 
for NO release activity. 
 
4.3.4  In Vitro Investigations of Intravenous Medications on Glucose Oxidase Activity 
After observing experiments in which glucose sensors lost significant sensitivity over the 
course of the IV implantation in pigs, as evidenced by increasingly smaller response to similar 
bolus injections of Dextrose, a series of in vitro investigations were conducted to determine if 
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intravenous drugs given through the jugular vein access to maintain a state anesthesia or raise the 
pig’s blood pressure were adversely affecting glucose oxidase activity of the sensors.  For these 
experiments, glucose sensors were placed in 0.1 M PBS, a baseline was recorded, and the solution 
was brought to 10 mM glucose.  Once a steady-state current was achieved for this concentration 
of glucose, several injections of the given intravenous drug were administered at a similar 
concentration to those given during the pig experiment.  By conducting these tests at a 10 mM 
glucose concentration, while H2O2 was actively being produced by the immobilized glucose 
oxidase, a drug’s potential inhibition of glucose oxidase activity or reaction with hydrogen 
peroxide should be rapidly observable.  A second calibration with fresh PBS and two 5 mM 
glucose injections conducted immediately after was designed to reveal if non-recoverable damage 
had occurred to the glucose oxidase activity.  Figure 4.13 a-d shows four such calibrations where 
four primary drugs (which typically were administered during the 20 h porcine in vivo studies): 
dopamine, vecuronium bromide, epinephrine, and heparin were injected into reaction cells 
containing functioning NO release glucose sensors.  Since there was no observable drop in current 
after the injection of each of these drugs, it was concluded that all four had no significant effects 
on glucose oxidase activity and were thus not responsible for the decreased current response from 
in vivo sensors. 
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Figure 4.13.  In vitro calibrations exploring the effects of intravenous drugs administered during 
the 20 h porcine experiments: (a) dopamine, (b) vecuronium bromide, (c) epinephrine, and (d) 
heparin on glucose oxidase activity of NO release glucose sensors. 
 
Another possible explanation for discrepancies between glucose sensors in bovine serum and 
actual in vivo implantation is the possible NO scavenging by hemoglobin, since serum has the 
majority of hemoglobin-containing red blood cells removed.  In a non-scavenging environment, 
excess NO produced from the PLA/DBHD/N2O2 layer can be oxidized at the platinum electrode 
surface at the operating potential of +0.600 V vs. Ag/AgCl, generating a nonzero background.  If 
enough of this NO were potentially scavenged by hemoglobin, this would cause a reduced 
background signal, and therefore, a smaller than expected intercept for the linear calibration 
equation.  A simple experiment designed to test this hypothesis is shown in Figure 4.14a-b.  First, 
NO release sensors were fabricated without glucose oxidase, so that the source of the sensor 
background was due to NO oxidation alone.  Then, oxyhemoglobin was produced from lyophilized 
hemoglobin and sodium dithionite in 0.1 M PBS while keeping the solution at 37.5°C to avoid 
current changes due to rapid changes in solution temperature.  A UV Visible absorbance spectrum 
(Figure 14a) was used to calculate the concentration of oxyhemoglobin, and the 0.1 M PBS 
solution containing the sensors was replaced with the hemoglobin solution.   
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Figure 4.14.  Effect of oxyhemoglobin on NO oxidation background.  A solution of 4.01mM 
oxyhemoglobin in 0.1 M PBS was measured via UV-visible spectrometry (a) and was placed into 
a cell containing NO release sensors (with no glucose oxidase) to observe oxyhemoglobin effects 
on the background current generated from nitric oxide oxidation. 
 
Although there was an initial decrease in current signal when the hemoglobin buffer first came 
into contact with the active sensors, the current response did not remain below the initial 
background NO oxidation baseline.  Instead, a slow drift to a baseline potential higher than the 
initial background was observed.  For most of these sensors, the total change was < 2 nA, which 
is a small Δi in comparison to changes in current from a glucose injection.  This small current 
increase most likely occurred due to the presence of electroactive interference species in the 
lyophilized hemoglobin powder. 
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The original protocol for glucose sensor fabrication called for two hours set aside for 
crosslinking of the glucose oxidase enzyme (in BSA suspension) onto the sensor cavity with 
glutaraldehyde.6  More recently, it was observed that by extending this crosslinking time overnight 
(> 10 h) improved the sensors long-term stability in in vitro bovine serum.  Thus, a set of sensors 
fabricated with extended glutaraldehyde crosslinking time was evaluated for analytical 
performance in bovine serum.  Following an overnight soak in serum of 8 h, the sensors were 
calibrated for glucose linearity ranging from the baseline serum glucose concentration of 6.6 mM 
to 21.2 mM via sequential injections of 2.0 M glucose in PBS.  Additional bovine serum that was 
not spiked with additional glucose was used to dilute the serum and modulate the glucose 
concentration to lower levels.  First 5.0 mL, then 10.0 mL, and finally 20.0 mL of unspiked serum 
were used for these dilutions.  The sensor responses to these glucose concentration modulations 
are shown in Figure 4.15.  There are variations in responses between individual sensors, but all 
sensors responded accordingly to the changes in glucose concentration.  Previously, extended time 
glucose measurements in bovine serum proved problematic.  Growth of aerobic bacteria would 
form a film or viscous layer within the serum sample, depleting the oxygen and either increasing 
the viscosity or causing the serum to partition into layers, resulting in glucose signal currents that 
rapidly declined.  However addition of 30 mg of sodium azide to the bovine serum helped prevent 
bacterial growth and allow for much longer measurements in the same serum solution.  For 8 h 
prior to and 47 h after the bovine serum calibrations, the sensors were placed into bovine serum 
with a constant concentration of 6.61 mM and 6.72 mM  glucose, respectively.  These experiments 
showcase the stability of the sensor’s steady-state current over an extended period of measurement 
(Figure 4.15 a-b).   
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Figure 4.15.  In vitro assessment of NO release glucose sensors (with extended glutaraldehyde 
crosslinking time) response to increasing and decreasing glucose concentrations in bovine serum 
through injections of glucose stock solution and dilutions of stock glucose, respectively. 
 
 
Figure 4.16.  In vitro bovine serum measurements of glucose steady-state response current for 
extended durations.  (a) represents an 8 h overnight serum signal stability assessment taken prior 
to the glucose modulations in Figure 4.15. (b) represents an extended multi-day serum signal 
stability assessment conducted immediately following the calibrations in Figure 4.15.  
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From these results, future NO release glucose sensors intended for evaluating in vivo analytical 
performance should adopt the extended glutaraldehyde crosslinking time.  Use of sodium azide 
should allow more reliable calibrations in bovine serum, especially those lasting longer than 
several hours. 
4.4  Conclusions and Future Directions 
In summary, the incorporation of E2As Elast-Eon as an outer coating and ester-capped 
PLA as a layer containing the NO release diazeniumdiolate species appears to provide an ideal 
combination coating to create improved intravascular electrochemical glucose sensors.  The use 
of E2As material serves a critical role by maintaining linear response to venous blood glucose 
concentrations up to 20.0 mM through its restriction of glucose diffusion to the glucose oxidase 
layer.  The PLA serves to maintain a local acidic environment within the layer containing 
diazeniumdiolated DBHD, so that NO release is prolonged.  The resulting NO release profile is 
sufficient to allow the continuous monitoring electrochemical glucose sensors to mimic the 
behavior of endothelial cells, granting them resistance to surface clot formation.  This 
thromboresistance is integral to preserve in vivo analytical performance and functionality.  The 
accuracy of NO-releasing glucose sensors was assessed by implantation within rabbit veins.  
Modulation of the animal’s venous blood glucose with dextrose bolus infusions can be used to 
help determine glucose sensor response time.  Control sensors quickly developed surface clots that 
increase sensor response time and decrease their measurement accuracy.  Nitric oxide release 
functionality helps prevent surface clot formation, which preserves fast sensor response times and 
accuracy in measuring glucose concentrations when results are compared with whole blood 
analyzer values obtained with discrete blood samples drawn from the animal.  In this preliminary 
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study, optimizing the NO release formulation and outer glucose restriction layer used to fabricate 
these devices has yielded improved in vivo performance.  
This chapter reports the first use of NO release intravenous glucose sensors for extended in 
vivo porcine studies using the 20 h porcine model, exceeding the previous 7-h threshold of the 
rabbit model.  Although additional future optimization is needed to improve the analytical 
accuracy of these sensors to the level of those found for the 7 h rabbit experiment, it can be 
concluded that the NO release chemistry still serves to enhance the thromboresistance of blood 
contacting sensor surfaces.  The two point calibration yielded the most accurate conversion of the 
sensor’s raw data to glucose values, but for future in vivo studies, it would be more ideal to use a 
one-point calibration, taken early in the experiment.  Additional in vitro experiments were 
conducted to identify and rule out potential sources of drift and measurement inaccuracy in the 
porcine model, but no clear root cause could be identified for the more significant sensor 
calibration drift in these experiments. 
Evaluation of membrane potentials developing across the polymers composing the outer layers 
of the glucose sensors revealed a negligible potential differential from only the E2As polyurethane, 
when in contact with bovine serum and a slight negative potential arising from a combination E2As 
and PLA/DBHD/N2O2 membrane.  Neither source likely contributes significant shifts in applied 
potential to the inner Pt working electrode of the sensors.  A bulk glucose diffusion test hinted that 
thick polyurethane membranes do not readily allow transit of glucose; instead, tiny pinholes in the 
thin layers of these polyurethanes used to coat glucose sensors are more likely responsible for 
glucose diffusion restriction and linear calibration behavior.  This hypothesis was confirmed 
through SEM imaging of the glucose sensor surface. 
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Extensive investigations to examine the effects of four key intravenous medications given 
during an in vivo porcine protocol on glucose oxidase activity revealed that dopamine, 
vercuronium bromide, epinephrine, and heparin do not cause any temporary or permanent 
inhibition of glucose sensor function.  Similarly, introduction of a large concentration of 
hemoglobin, which acts as a rapid NO scavenger in whole blood, did not scavenge enough local 
NO in the vicinity of the Pt electrode cavity of the glucose sensors to significantly reduce the NO 
oxidation background signal. 
Following in vitro tests hinting that increased time allotted for the crosslinking reaction of 
glutaraldehyde yielded sensors with increased stability in bovine serum, a series of extended 
steady-state stability tests and glucose calibrations were conducted on sensors allowed to crosslink 
overnight, nearly 5x the time originally reported.  It is suspected that this additional crosslinking 
time offers additional resistance of the immobilized glucose oxidase enzyme to damaging 
substrates or inhibiting molecules encountered in whole blood.  The sensors fabricated with the 
revised crosslinking protocol showed long-term stability at a constant serum glucose concentration 
as well as continuous time trace measurements that followed rising and falling serum glucose 
concentrations.  Additional NO release glucose sensors fabricated from the designs presented 
herein, especially those undergoing in vivo testing, should capitalize on the benefits provided by 
an increased crosslinking period. 
For future in vivo experiments, it is expected that both the thromboresistance and improved 
analytical measurement accuracy will be observed with additional sensors utilizing 
diazeniumdiolate-based NO release, E2As polyurethane outer membranes, annealed Nafion, and 
extended glutaraldehyde crosslinking as novel design elements. 
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CHAPTER 5 
TOWARD ENHANCING THE BIOCOMPATABILITY OF COMMERCIAL 
INTRAVENOUS INTERMITENTLY MONITORING GLUCOSE SENSORS VIA 
TRANSIENT NITRIC OXIDE RELEASE  
5.1  Introduction 
At present, no commercial product exists in the United States market (having attained FDA 
approval) for real-time measurement of blood glucose levels for the intended use of tight glycemic 
control.  The GlucoClear Peripheral IV Sensor (Fig. 5.1), developed by Edwards Lifesciences, is 
a device that measures blood glucose intermittently, by drawing a small volume of intravenous 
blood back over the sensor every 5 min through a 20 gauge IV catheter1-3.  When the device is not 
undergoing blood sampling or blood glucose measurement mode, a pump continually flushes the 
line with a glucose calibrating solution.  The glucose sensor component used within the system is 
based on a commercially-licensed Dexcom glucose sensor,4,5 designed to function for up to 72 h.  
By using Flavin Adenine Nucleotide (FAD) as a co-enzyme for the immobilized glucose oxidase 
and a multilayer hydrogel membrane, the sensor gains selectivity over potential interference 
species, while providing a the sensor linear behavior and glucose diffusion restriction through a 
polyurethane insulating layer.  The sampling line catheter contains two adjacent sensing 
electrodes, one with the enzyme, and the second without, to create an internal measurement 
reference and further ensure the selectivity of the observed current response.  However, without 
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added thromboresistance functionality, the blood contacting portion of the device can develop 
clots, preventing accurate glucose measurement.  In this product, available on the European 
commercial glucose sensor market, addition of heparin to the continuously-flushing/calibrating 
solution helps prevent blood clotting for the duration of the device lifetime; however, use of a 
nearly continuous heparin infusion has hindered FDA-approval for US markets, owing to the 
potential bleeding risks of infusing even low doses of heparin into intensive care unit patients. 
 
Figure 5.1.  The Edwards Lifesciences GlucoClear System, featuring: the sensor housing (left) 
containing the intravenous sampling line with dual-electrode configuration, the solution pump and 
monitor (top right), and the entire system (bottom right).1-3  
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Figure 5.2.  A diagram of the Edwards glucose sensors.  Each sampling line contains two of these 
sensors, one with an enzyme layer, and one without enzyme (to serve as an internal reference). 
A research engineer from Edwards approached our laboratory with the idea of a collaboration 
project that would combine nitric oxide (NO) release chemistry with the GlucoClear system as an 
alternative method of imparting thromboresistance to the sensor.  If this could be accomplished, it 
would obviate the need to add heparin into the calibrating/flush solution.  S-Nitroso-N-
acetylpenicillamine (SNAP), an S-nitrosothiol, has been previously reported to provide stable NO 
release in an E2As polyurethane.6-8  Active NO release incorporated into blood contacting polymer 
surfaces functions to mimic the endogenous NO flux of 0.5 x 10-10 mol cm-2 min-1 by endothelial 
cells lining all blood vessels, which helps in preventing platelet activation.9  By incorporating 
SNAP-based NO release into the catheter tubing of the sample line of the Edwards system, clot 
formation on the catheter surface could be reduced or prevented without a need for heparin 
infusion.  An even higher priority is preventing clot formation on the sensor surface.  Based on the 
design of GlucoClear system, the sensor spends the majority of the time in contact with the 
calibrating solution, which makes it unique from the other continuously-monitoring intravenous 
sensors discussed in Chapter 4 of this dissertation.  Since this solution will not scavenge NO 
immediately, as is the case whole blood, NO should be able to diffuse from the catheter wall 
source, through the aqueous calibrating solution (since no hemoglobin will be in this region after 
the flush with the calibrating solution), and partition into the thin polyurethane coating on the 
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sensors during the calibration phase.  When the device undergoes the blood draw phase, this 
transient NO accumulated within the polyurethane layer of the sensor should be able to provide 
temporary NO release from the sensor surface, and therefore impart some thromboresistance.  The 
goal of this preliminary study was to assess whether creating a NO release catheter into which the 
GlucoClear sensors are placed, could provide a level of NO release to the surface of the sensors. 
 
5.2  Experimental 
5.2.1  Materials 
Individual glucose sensors, pellethane tubing, and sensor housings were a generous gift from 
Edwards Lifesciences.  N-Acetyl-DL-penicillamine, tetrahydrofuran, iron(III) chloride (FeCl3), 
and ethylenediaminetetraacetic acid were obtained from Sigma-Aldrich (St. Louis, MO).  Sodium 
phosphate dibasic heptahydrate (Na2HPO4 · 7H2O), sodium phosphate monobasic monohydrate 
(NaH2PO4 · H2O) were purchased from Amresco, Inc. (Solon, OH).  Sodium chloride (NaCl) is a 
product of Research Products International Corp. (Mt. Prospect, IL).  Potassium chloride, sulfuric 
acid, methanol, and dichloromethane were from Fisher Scientific (Pittsburgh, PA).  Teflon-coated 
silver wires were products of A-M Systems (Sequim, WA).  Standard silicone tubing, composed 
of Dow Corning Silastic pharmaceutical/biomedical grade, with platinum-cured silicone, was 
produced by HelixMark Medical, LLC (Carpinteria, CA) and purchased through VWR 
International (Chicago, IL). 
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5.2.2  SNAP Synthesis 
SNAP was synthesized using a modified version of a previously reported method.6,7,10  Briefly, 
an equimolar ratio of NAP and sodium nitrite was added to a 1:1 mixture of water and methanol 
containing 2 M HCl and 2 M H2SO4.  After 30 min of stirring, the reaction vessel was cooled in 
an ice bath to precipitate the green SNAP.  These SNAP crystals were then dried and isolated with 
vacuum filtration and stored in a -20°C freezer until needed. 
5.2.3  SNAP Loading of Sensor Housing Tubing 
To load the synthesized SNAP into lengths of commercial tubing, the SNAP was first dissolved 
into a solvent or solvent mixture that was capable of both swelling the tubing as well as having a 
desired solubility for SNAP.  In the case of the pellethane tubing originally used in the Edwards 
GlucoClear system1, a 0.9/0.1 mixture of methanol:dicholomethane with 200 mg/mL SNAP served 
as the impregnation solution, since tetrahydrofuran (THF) dissolves pellethane.  The tubing 
samples were soaked overnight, briefly rinsed with DI water, and then dried in a hood vacuum 
under a cardboard cover for 24 h. 
Due to insufficient loading of the pellethane tubing, HelixMark silicone rubber tubing was 
suggested as an alternative housing/catheter tubing for the sensors.  SNAP can be loaded into 
silicone rubber efficiently by using THF as a solvent6-8.  Due to crosslinking in the silicone rubber 
structure, THF swells such tubing rather than dissolving the material due to the crosslinked 
structure of silicone rubber, and also has a high solubility for SNAP, making it the ideal solvent 
for loading silicone rubber.  Again, 200 mg/mL SNAP in THF solutions were injected into glass 
swelling chambers containing tubing samples for the loading.  Initially, the loading time was 24 h, 
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but given the small diameter and thickness of the tubing wall (1.65 mm o.d., 0.76 mm i.d., 0.445 
mm wall thickness), loading time was reduced to 2 h for later experiments. 
5.2.4  Nitric Oxide Release Measurements  
Transients of nitric oxide released from these Edwards glucose sensors after they were placed 
in solution within the NO release tubing was monitored via chemiluminescence using a Sievers 
Nitric Oxide Analyzer (NOA) 280i (Boulder, CO).  The source SNAP impregnated SR catheters 
were soaked in 0.1 M PBS, pH 7.4, containing 100 µM EDTA in a 37.5°C oven.  The Edwards 
commercial glucose sensors were also soaked in 0.1 M PBS, pH 7.4 with 100 µM EDTA.  One at 
a time, sensors were placed inside the SNAP-loaded tubing for a 5 min charging time, allowing 
NO to diffuse from the catheter surface to the polyurethane surface of the sensors and favorably 
partition into that layer.  At the end of the charging period, they were placed into an amber glass 
NOA reaction cell containing 0.1 M PBS, pH 7.4 with 100 µM EDTA, and the NO released from 
sensors could be measured and recorded by the NOA as function of time.  The data were converted 
from raw ppb gas phase concentration values to flux units (based on an approximation of the sensor 
surface area) to compare it to the 0.5 x 10-10 mol cm-2 min-1 minimum threshold for endogenous 
NO release from endothelial cells.9  The NO release of the source catheter was also measured 
during the experiments. 
The glucose sensing functionality of the commercial sensors was also assessed via calibrations 
using 4-channel BioStat potentiostats (ESA Biosiences Inc., Chelmsford, MA).  The potential 
applied to the inner Pt wire was +0.600 V vs. Ag/AgCl reference in a 0.1 M phosphate buffered 
saline (PBS), pH 7.4, test solution at 37.5°C. 
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5.3  Results and Discussion 
5.3.1  NO Release from Pellethane and Silicone Rubber Tubing 
Pellethane tubing was first considered for SNAP-loading, given that it is the original material 
used in the Edwards GlucoClear system1.  However, it became readily apparent from initial NO 
release measurements that only a very small amount of SNAP can be loaded into this tubing, 
perhaps due to a low solubility of SNAP within the polymer phase.  In Figure 5.3, the flux from 
the pellethane source catheters begins below 0.5 flux units, and is exhausted 3 d after initial soaking 
in PBS.  This plot served as evidence to consider an alternate polymer material for the catheters. 
 
Figure 5.3.  NOA measurement of NO release from SNAP-loaded pellethane tubing showing the 
need to use an alternate material or polymer for efficient SNAP loading and adequate levels of NO 
release. 
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SNAP loading of silicone rubber tubing yielded far better NO release properties.  As shown in 
Figure 5.4, the silicone rubber HelixMark tubing shows NO release above 0.5 flux units for most 
of their 9 d NO release lifetime after initial soaking in PBS for 2 h.  The ideal length of catheter 
needed for use with the Edwards system was 55 cm, so segments >55 cm were loaded with SNAP.  
Portions from different regions of the catheter were measured to ensure consistent loading 
throughout the catheter’s entire length.  An average NO flux for n=5 catheters is reported. 
 
Figure 5.4.   NOA cataloging of NO release from SNAP-loaded silicone rubber tubing when stored 
in 0.1 M PBS, pH 7.4, at 37.5 °C.  Release remained at or above 0.5 flux until 9 d after initial 
buffer exposure. 
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5.3.2  Transient NO Charging of Glucose Sensors 
Following the confirmation that SNAP-loaded silicone rubber tubing could be successfully 
manufactured into NO releasing tubing, it was possible to assess if an appreciable amount of NO 
could partition into the polyurethane layer of the Edwards sensors if they were placed within a 
SNAP-loaded SR tubing for 5 min charging time (in the presence of PBS buffer that filled the 
tubing).  Figure 5.5a shows the transient NO release from Edwards commercial sensors after 5 
min of charging within the source SNAP-loaded catheter.  NO release lasts for 5-6 min at or 
above a flux of 0.5 x 10-10 mol cm-2 min-1 indicating that NO was successfully able to partition 
into Edwards sensor, likely the outer polyurethane layer.  Figure 5.5b shows the NO release of 
the source SNAP-loaded SR catheter, at its baseline NO release, which was about 68 ppb or 1.0 
flux units.   
117 
 
 
Figure 5.5.  (a) Transient nitric oxide release from the surface of the Edwards commercial glucose 
sensors following 5 min soaking inside a SNAP-loaded silicone rubber catheter in 0.1 M PBS, pH 
7.4, 37.5°C.  (b) Nitric oxide release from the source SNAP-loaded SR catheter of 68 ppb, or 
around 1.0 flux units. 
(a) 
(b) 
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The efficiency of the transient NO charging appears to be a function of the NO release from 
the source catheter to a greater extent than the amount of time allow for charging.  Since the 
polyurethane layer on the sensors is very thin, there should be a threshold of a maximum 
concentration of NO able to partition into the polyurethane layer based on the thickness of that 
layer, such that beyond a certain charging time, no additional transient NO could partition into the 
polyurethane layer no matter what duration the soaking/charging occurred.  In Figure 5.6a, 
additional testing was conducted to examine NO charging of the Edwards sensors; however, the 
maximum NO release spikes did not match those of Fig. 5.5a though they still released transient 
NO at or above 0.5 flux for 5-8 minutes.  However, as shown in Figure 5.6b, for these follow-up 
experiments, the source SNAP-loaded SR catheter had an NO release about one half that of the 
earlier test.  Several repetitions of such studies were conducted, and the data behavior more often 
resembled that of Fig. 5.6a-b rather than Fig 5.5a-b.  This could result from the efficiency of the 
SNAP loading of the source catheter.  If the THF solvent used for loading was old and no longer 
anhydrous from exposure to air and water vapor for an extended amount of time, this could cause 
the swelling and SNAP  partitioning into the silicone rubber to be less efficient, or cause the SNAP 
to begin decomposing to release NO prior to the actual loading process.  It is also suspected that 
due to the thin wall thickness of the source catheter, beyond a certain time point, additional SNAP 
cannot be loaded. 
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Figure 5.6.  (a) Additional experiment showing transient NO release from the surface of the 
Edwards commercial glucose sensors following 5 min soaking inside a SNAP-loaded silicone 
rubber catheter in 0.1 M PBS, pH 7.4, 37.5°C.  (b) Nitric oxide release from the source SNAP-
loaded SR catheter of 30 ppb, or 0.45 flux units. 
(a) 
(b) 
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A simple model of NO diffusion was assembled as a collaboration with Hang Ren of the 
Meyerhoff lab using the COMSOL Multiphysics® modeling software.  As observed in Figure 5.7 
(a), the model represents the NO concentration gradient from the inner diameter of the SNAP-
loaded source catheter to the outer polyurethane layer of the Edwards sensor.  It assumes a charging 
time of 5 min, an NO diffusion coefficient (D) equal to 1.2 x 10-6 cm2 s-1, and a partition coefficient 
(K) for NO into polyurethane of 2.5.  The concentration decreases slightly from 2.83 to 2.71 x10-
5 M from the inner surface of the source catheter to the polyurethane surface.  An expanded view 
of the thin polyurethane layer can be seen in Figure 5.7b, and here the NO is able to build a higher 
concentration of 6.77 x 10-5 M than that present in the surrounding PBS solution, based on the 
favorable partitioning of NO into polyurethane.  It can also be seen that the concentration gradient 
throughout the layer is consistent, although models assuming thicker polyurethane outer layers 
would likely have greater NO concentration in the area nearest to the surface.  Without the presence 
of scavenging hemoglobin, it is certainly possible, based on this model, for transient NO to 
accumulate within the outer polyurethane surface of the glucose sensors, and to later be released 
back into solution.  This would provide the sensors with some degree of thromboresistance when 
they are in direct contact with whole blood (as is the process in the Edwards GlucoClear system).  
However, by using silicone rubber tubing with a thicker wall and a similar inner diameter, it may 
be possible to boost the NO release of the source catheter to a higher level, and achieve a greater 
NO concentration within the polyurethane outer sensor layer and/or increase the duration of 
transient NO release from the sensor surface. 
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Figure 5.7.  (a) Nitric oxide concentration gradient model from the inner surface of the SNAP-
loaded source catheter to the polyurethane surface of the Edwards commercial glucose sensor.  (b) 
Expanded NO concentration gradient model within that polyurethane surface of the Edwards 
commercial glucose sensor. 
(a) 
(b) 
D=1.2x10-6 cm2 s-1, K=2.5, time=300 s 
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A second theoretical model illustrated in Figure 5.8a shows the NO concentration gradient 
assuming that the layer coating the glucose sensor was composed of silicone rubber, rather than 
polyurethane, but with the same charging time of 5 min.  The concentration of NO again decreases 
from 2.79 to 2.67 x 10-5 M as one moves from the inner surface of the source catheter to the sensor 
surface.  However, since the model for silicone rubber has a much more favorable partition 
coefficient (K) of 7, and an increased diffusion coefficient of 1.2 x10-6 cm2 s-1, the concentration 
within the sensor coating is around three times that of the polyurethane layer model, 1.87 x 10-4 
M.  Again, the layer is very thin, so the NO concentration within that silicone rubber layer is 
consistent throughout.  One could make a prediction that if a polyurethane had silicone segments 
within its structure, like E2As,11 perhaps more efficient transient NO accumulation could occur. 
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Figure 5.8.  (a) Nitric oxide concentration gradient model from the inner surface of the SNAP-
loaded source catheter to a theoretical silicone rubber surface the thickness of the Edwards 
commercial glucose sensor.  (b) Expanded NO concentration gradient model within that silicone 
rubber surface of the Edwards commercial glucose sensor. 
 
However, modeling of the NO release from such a surface, seen in Figure 5.9, suggests that 
transient NO from a 5 min charging time would be depleted much faster than the 5-8 min shown 
in the experimental data.  This would indicate that the actual thickness of the outer layer of the 
Edwards commercial system is greater than the value used in the model, as a thicker layer could 
accumulate a greater reservoir of transient NO that would accordingly, take a longer time to 
exhaust.  The actual diffusion constant and partitioning coefficient values are also very specific to 
chemical structure, such that they can vary between polyurethanes depending on the soft and hard 
segment composition. 
D=2.5x10-6 cm2 s-1, K=7.0, time=300 s 
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Figure 5.9.  Comparison model of theoretical NO release from a polyurethane (PU)-based outer 
glucose sensor coating versus a silicone rubber (SR)-based coating.  An outer sensor coating 
composed of segments more similar in structure to silicone rubber would likely show a longer 
duration of NO release.  The actual thickness of the outer polyurethane is very likely greater than 
the thickness of the layers for the model, which would also result in more prolonged NO release. 
 
5.3.3  Analytical In Vitro Performance of Edwards Glucose Sensors  
The Edwards commercial glucose sensors are fabricated by machine process (Figure 5.10) 
rather than individually assembled by hand, resulting in greatly reduced variation in sensor 
response between individual sensors.  In addition, the layers of polyurethane applied over the 
enzyme layers are both very thin and extremely consistent across a given lot, granting 
exceptionally fast response times for nearly every sensor.  In comparison, hand-fabricated sensors 
with only polyurethane outer coatings (like those in Chapter 2) have significantly faster response 
times than those assembled with several coatings of NO releasing compounds, such as the 
PLA/DBHD/N2O2 glucose sensors described in Chapter 4.  One specific advantage of using 
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indirect NO release through transient diffusion and partitioning is that the rapid response time of 
the sensor remains uncompromised, which can be quite challenging to achieve when sensors are 
prepared with a directly applied NO release coating on their surfaces (see Chapter 4).  
In addition, it was of utmost importance to also conduct glucose calibrations of the sensors 
following the transient NO release testing to ensure that glucose oxidase activity, linear range, and 
response time were not damaged or adversely effected by the NO charging or release 
measurements.  Figure 5.11 shows a typical glucose calibration of the Edwards sensors after NO 
release testing.  Glucose oxidase activity and linear range are superb, and sensor response time is 
very rapid, demonstrating that the transient NO exposures do not affect analytical performance of 
the glucose sensors for their intended function. 
 
Figure 5.10.  Outer layer layer-by-layer assembly array for Edwards commercial glucose sensors. 
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Figure 5.11.  In vitro glucose calibration of Edwards commercial glucose sensors to assess 
preservation of glucose oxidase activity, sensor linearity, and sensor response time following 
transient NO release testing. 
 
5.4  Conclusions and Future Directions 
Incorporation of NO releasing chemistry offers a great advantage of thromboresistance to 
sensors intended for blood-contacting applications.  Previously published work has focused 
primarily on coating glucose sensor with a NO releasing layer composed of diazeniumdiolated 
compounds or more robust S-nitrosothiols like SNAP.  However, in this specific case, the Edwards 
GlucoClear system is only exposed to whole blood during a small portion of its lifetime, giving 
the flexibility to localize the source of NO release chemistry to the catheter housing of the sensor, 
rather than the sensor surface, as would be required of sensors in constant blood contact (due to 
rapid NO scavenging by hemoglobin in blood).  Instead, if NO is able to diffuse through the 
aqueous catheter calibration solution and partition into the thin outer polyurethane layer of the 
commercial sensor for the 5 min interval between blood measurements,  it can theoretically achieve 
a higher NO concentration than is found in the solution, due to favorable diffusion and partitioning 
into the polyurethane layer.  Preliminary tests show that transient NO release accumulated from 
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this charging phase can then release for a duration of at least 5 min once the sensor is isolated from 
the source catheter, as would occur if the catheter were filled with blood.  Additional optimization 
involving SNAP-loaded catheters of different sizes (resulting in different source NO flux values) 
or additional concentrations of SNAP-loading impregnation solutions could be conducted to 
determine the maximum values for peak and longest-lasting NO release.  However, the 
experiments described in this chapter are proof-of-concept that glucose sensor thromboresistance 
through transient NO release is a worthwhile alternative to use of heparin for the intermittent-
sampling GlucoClear device. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1  Summary of Results for Dissertation Research 
The benefits of tight glycemic control range from minimizing complications for diabetic 
patients to improving patient outcomes for all critically-ill patients, even those without diabetes.  
Monitoring a patient’s blood glucose levels continuously or intermittently via electrochemical 
glucose sensors offers an advantage of detecting and predicting increasing/decreasing trends over 
benchtop blood analyzers, which only offer discrete time-point measurements from drawn samples 
taken every few hours.1-3  Electroactive species present in the complex matrix of whole blood can 
cause inaccurate measurements stemming from the interference currents they can generate without 
the addition of selectivity-enhancing layers.  Development of implantable glucose sensors has also 
been impeded by the body’s immune and foreign body response to implanted devices, which often 
results in surface clotting and performance failure when such devices are placed intravenously.  
Therefore, development of methods to enhance the biocompatibility of implantable glucose 
sensors, with respect to selectivity for current response arising only from glucose as well as sensor 
surface functionalization to add thromboresistant capability, are of great research and commercial 
interest.  Chapter 1 discussed the wide range of glucose sensing devices developed through 
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academic research or commercially produced products, and the wide variety of biocompatibility-
enhancement strategies that have yielded various levels of effectiveness to date. 
Previous intravenous glucose sensor designs required a combination of layers to provide sensor 
selectivity over electroactive interference species such as ascorbic acid, uric acid, and 
acetaminophen.  Often, a Nafion layer was applied first, providing selectivity over negatively 
charged species such as ascorbic and uric acid.  This would be followed by addition of a size 
exclusion layer, formed by the electropolymerization of 1,3-diamnobenzene and resorcinol within 
the pores of the Nafion layer.4-9  However, studies of Nafion films, for applications other than 
implantable sensors, that were subjected to an annealing process showed increased rejection of 
large anionic species, indicative of reorganization of the internal sulfonate groups within the 
Nafion film structure, resulting in smaller hydrophilic channels.10-12  Application of annealed 
Nafion layers to implantable glucose sensors could therefore enhance the sensor selectivity.  
Indeed, in Chapter 2, glucose sensors fabricated with annealed Nafion layers exhibited enhanced 
selectivity (over non-annealed films) over ascorbic and uric acid, reducing their interference signal 
contribution to ≤ 3 % of the signal measured for typical blood glucose concentration (5 mM) for a 
duration of 8 d.  The variation in selectivity over ascorbic and uric acid between individual sensors 
was also smaller than glucose sensors fabricated by previously reported methods using a non-
annealed Nafion selectivity-enhancing layer.4,6,13,14 
In Chapter 3, a collaboration with researchers at the University of Pennsylvania who are 
experts on functionalizing blood-contacting polymeric surfaces with CD47 protein15-17 led to the 
development of intravascular glucose sensors with CD47 successfully functionalized onto the 
E2As Elast-Eon polyurethane outer coating of these devices.  The CD47 protein endogenously 
functions as a marker of self, being ubiquitously expressed within the cell membranes of many 
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cells.  When it undergoes a temporary “handshake” interaction with its cognate receptor protein, 
SIRPα, expressed within the cell membranes of inflammatory cells (e.g., platelets, neutrophils, 
etc.), the inflammatory cells are not activated and immune response and coagulation cascades are 
not triggered.18-24  Preliminary in vitro calibrations, conducted before and after CD47 
immobilization, show that the steps required for immobilization protocol do not adversely 
influence the glucose response properties of such sensors.  Glucose sensors surface-functionalized 
with recombinant human CD47 retain their linear response range and glucose oxidase activity after 
the surface functionalization procedure.  In addition, testing of selectivity before and after CD47 
functionalization, revealed that an acceptable level of selectivity over electroactive interference 
species based on the use of an annealed Nafion inner layer was also maintained throughout the 
immobilization procedure. 
In Chapter 4, intravenous glucose sensors featuring a nitric oxide (NO) releasing layer 
composed of diazeniumdiolated N,N’-dibutyl-1,6-hexanediamine (DBHD/N2O2), an NO donor 
molecule, suspended in a pH-controlled poly(lactic acid) PLA matrix, were examined for 
continuous in vivo monitoring of glucose.  This research expanded upon prior studies regarding 
the use of intravenous NO releasing glucose sensors implanted within rabbits.4,6,14  In this new 
work, blood glucose concentration was modulated via intravenous injections of dextrose, and the 
sensor response was shown to correctly report the rising and falling blood glucose concentrations, 
which were compared alongside discrete time points of measured venous blood glucose values, as 
measured by a benchtop whole blood analyzer.  In addition, the NO release glucose sensors of 
similar design were used in preliminary extended duration 20 h porcine studies to generate 
continuous time traces of venous blood glucose, as modulated with dextrose injections.  Due to 
significant sensor calibration drift during the course of these 20 h porcine experiments, it was 
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difficult to convert the raw current values measured by the glucose sensors into venous blood 
glucose concentration values that matched with the discrete in vitro whole blood values.  A two 
point calibration model for data interpretation, conducted several hours after the start of the 
experiment, proved to yield a better fit model for determining glucose concentration values than a 
model based on in vitro calibration in bovine serum prior to in vivo implantation or a one-point 
calibration taken from a discrete whole blood in vitro measurement at the start of the experiment.  
As a direct result of calibration difficulties for these 20 h in vivo studies, in vitro investigations 
were conducted to determine the underlying cause for the calibration drift.  The intravenous drugs 
dopamine, vecuronium bromide, epinephrine, and heparin, which are administered to the pig 
throughout the course of the experiment to regulate metabolic functions, were individually 
determined not to adversely affect the glucose response properties of the sensors.  Hemoglobin, an 
element found in whole blood in high concentrations (in red blood cells) but not in bovine serum 
was suspected to scavenge NO released at the sensing surface, thereby reducing the oxidation 
current background.  However, an in vitro benchtop experiment showed that introduction of a 4.01 
mM oxyhemoglobin solution did not result in a decreased background current response from the 
sensor ruling out this mechanism as the root cause of the calibration problems.  Diffusion cell 
experiments ruled out the buildup of a membrane potential in serum as a source of drifting sensor 
signal due to changes in applied voltage to the underlying Pt working electrode of the implantable 
glucose sensor.  SEM imaging determined that pinholes in the outer polyurethane membrane, 
rather than bulk diffusion across the layer, were likely responsible for the limited diffusion of 
glucose that provides the sensors their linear range.  Eventually, it was determined that increasing 
the duration of time allotted for glucose oxidase to be crosslinked and immobilized during sensor 
fabrication from 2 h to >10 h increased the stability of glucose oxidase activity in a bovine serum 
133 
 
matrix.  A series of extended in vitro calibrations in bovine serum as well as analysis over a >45 h 
period yielded enhanced current stability at a constant serum glucose concentration.  NO release 
glucose sensors with increased crosslinking time displayed analytically accurate glucose 
measurements in bovine serum, with both increasing and decreasing concentration modulations 
after an extended (>8 h).  This suggests that glucose sensors with increased cross-linking time will 
likely better resist in vivo calibration drift in future animal testing of the NO release glucose 
sensors. 
In Chapter 5, a method to enhance the thromboresistance via NO release of a commercial 
system designed by Edwards Lifesciences to aid in tight glycemic control was examined.  In its 
current form the system functions by drawing venous blood samples through an IV access and 
measuring blood glucose in those samples intermittently every 5 min via a glucose sensor placed 
within the catheter.  When blood is not drawn back over the sensor, the sensor surface is in direct 
contact with a stream of aqueous solution containing a known glucose level (used for continual 
calibration of the sensors) as well as heparin (to prevent clot formation on the sensor surface).  
Since the majority of the time the sensors would be in the buffered, aqueous calibration solution, 
rather than in constant contact with whole blood, it was reasoned that incorporating active NO 
release within the catheter tubing that surrounds the electrochemical glucose sensor would be a 
viable alternative to attempting to directly apply an NO releasing coating to the sensor surface, 
thereby preserving the rapid sensor response time and low variability of behavior between 
individual, commercially-produced sensors.  Without the presence of hemoglobin to act as a rapid 
NO scavenger, the NO released from the inner wall of the tubing could diffuse to the thin 
polyurethane outer surface of the glucose sensors and favorably partition into that material.  If 
partitioning of NO into the polyurethane over the surrounding solution was favorable, the 
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polyurethane layer could be “charged” with an elevated concentration of transient NO, which 
could be subsequently released during the blood-contact phase of calibration.  This would provide 
the sensor surface with enhanced thromboresistance obviating the need for heparin in the 
calibration solution.  While the original pellethane catheter tubing used by Edwards to house the 
sensors in the GlucoClear system could not be effectively loaded with S-nitroso-N-
acetylpenicillamine (SNAP), an NO releasing donor molecule, silicone rubber catheters of similar 
size can be loaded with SNAP and provide sustained NO release.  Selection of silicone rubber 
catheters for this application was based on recently published results regarding a solvent swelling 
method to incorporate SNAP into silicone rubber tubing.25  It was essential to determine if the 
source SNAP-loaded catheter could provide an adequate measure of NO sufficient to allow the 
secondary transient NO release from the glucose sensor surface.  Placement of sample commercial 
sensors within SNAP-loaded SR tubing for a duration of 5 min to charge the polyurethane layer 
with transient NO revealed a sufficiently high enough NO concentration within the polyurethane 
which provided at least 5 min of NO release from the sensor surface.  However, the magnitude of 
transient NO release did appear to depend upon the flux level from the SNAP-loaded source 
catheter surrounding the sensor, and a source catheter with less than desired surface flux yielded a 
proportionally lower transient NO release from the glucose sensors.  Glucose calibrations 
conducted on these sensors following NO release testing confirmed no adverse effects to the 
glucose response properties of the sensor after exposure to the NO coming from the SNAP-doped 
catheter. 
Diffusion and partitioning modeling of NO by COMSOL® Multiphysics via a collaboration 
with Hang Ren shed insight on the mechanics of this method of secondary NO release.  The model 
is constructed using diffusion and partition coefficients for common polyurethane structures.  
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Modeling results revealed that a 5 min charging period of a glucose sensor within an NO releasing 
source catheter of given dimensions (i.d.) would accumulate an elevated concentration of NO as 
compared to the solution in the catheter surrounding the sensor.  In addition, the NO concentration 
within that layer is expected to be uniform.  A second model assuming a sensor outer layer with 
properties akin to silicone rubber showed a similar ability to uniformly charge the outer layer with 
NO, except that the transient NO could accumulate to an even higher concentration within the 
sensor’s outer layer.  Assuming that the commercial sensors were fabricated with a polyurethane 
layer with a high percentage of poly(dimethylsiloxane) segments and characteristics, its behavior 
would likely be an intermediate between the two models. 
6.2  Future Work 
Glucose sensors with annealed Nafion were shown to provide a significant increase in 
selectivity over the negatively charged interference species of ascorbic and uric acid as compared 
to previous fabrication techniques.  In future research, one could conduct daily selectivity 
experiments for a longer duration (10-20 d) in order to determine the lifetime of this enhanced 
selectivity before significant degradation occurs to the annealed Nafion layer.  In vitro experiments 
are the best way to evaluate selectivity, as the exact amount of the interference species can be 
controlled, although spiking a bovine serum sample or intravenously administering a bolus of 
interference species could be pursued to give an approximation of the actual in vivo selectivity (in 
the presence of blood components).  If the sensor fabrication protocols for annealed Nafion are 
closely followed, the Nafion film and its selectivity character are quite reproducible; thus it is 
anticipated that these coatings should continue to maintain selectivity when used for in vivo 
experiments. 
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The majority of work conducted in Chapter 3 with the CD47 surface-functionalized glucose 
sensors serves as proof-of-concept, and the next logical progression will be to determine whether 
immobilized CD47 confers sufficient hemocompatibility to enable the glucose sensors not to 
activate the coagulation cascade when tested in vivo.  Studies to assess the CD47’s antithrombotic 
activity when immobilized on implantable chemical sensors are currently being planned.  To 
answer an additional key question, a comparison study should be conducted to determine whether 
immobilized CD47 provides an equivalent level of anti-platelet activity as sensors prepared only 
with NO releasing capability.  Perhaps sensors prepared with a combination of both immobilized 
CD47 and NO release will be the most desirable approach to enhancing biocompatibility (see 
Figure 6.1).  To potentially pursue this approach, the NO releasing polymeric coating would need 
to first be applied as an inner layer and then CD47 could be functionalized on the outermost surface 
of a thin additional layer of polyurethane.  Since NO is readily permeable through polyurethanes, 
the addition of this layer should have little effect on the NO release flux of such a sensing device.  
The critical component that will need to be controlled in this configuration is the length of time 
that the sensor is hydrated during the CD47 immobilization process, since NO release will occur 
over this period and hence decrease the overall NO reservoir remaining within the sensor.  
However, if the CD47 reaction times can be limited to 8 h or so, and the glucose sensors can be 
immediately dried thoroughly, the loss of NO will be minimal. 
137 
 
 
Figure 6.1.  Glucose sensor incorporating an underlying NO releasing layer and then CD47 
immobilization on the exterior of the outer polyurethane top coat. 
 
Identification of increased glutaraldehyde crosslinking reaction time allotted to the glucose 
oxidase enzyme layer is a critical step to enhancing current signal stability in surrounding 
environments and should allow the continuation of long-term in vivo implantation studies for the 
NO release glucose sensors described in Chapter 4.  Sensors fabricated with these protocol changes 
should experience significantly less calibration drift, resulting in a greater degree of analytical 
accuracy for in vivo blood glucose measurements with time.  Additional in vivo data showing 
accurate continuous time trace measurements as blood glucose is modulated with intravenous 
dextrose are needed for publication of the 20 h in vivo studies.  Other researchers within the 
Meyerhoff lab are developing variations on designs for NO release glucose sensors.  Though it has 
been shown to be a more stable NO donor, SNAP cannot be directly used in place of DBHD & 
N2O2 for the needle type glucose sensors, due to insufficient duration of NO release.  Dr. Xuewei 
Wang, a postdoctoral fellow in the Meyerhoff laboratory, has developed a catheter-based glucose 
sensor that does not directly have an NO releasing layer applied to its surface.  Rather, glucose 
138 
 
sensors with only polyurethane coatings are placed inside small pre-swelled and pre-SNAP-loaded 
catheters, which do provide NO release for >14 d, while maintaining glucose response properties.  
A similar approach using a dual-lumen silicone rubber catheter, where one lumen contains a 
glucose sensor (without an NO releasing layer) and the other lumen generates NO 
electrochemically from nitrite reduction.  If additional difficulties arise from in vivo testing of the 
specific NO release glucose sensor design detailed in Chapter 4, these other NO release strategies 
could be further developed. 
Continuation of the preliminary testing in Chapter 6 could immediately involve the SNAP-
loading of additional silicone rubber catheters, preferably of increased wall thickness, to determine 
if a loaded catheter with an increased surface source NO flux could further increase the 
concentration of transient NO accumulated and released from the Edwards sensor’s polyurethane 
layer.  If the specific type of polyurethane used to fabricate the sensors can be determined, a more 
specifically tailored computer model could be constructed, reflecting its specific NO diffusion and 
partition coefficients.  Eventually, a mimic of the whole Edwards GlucoClear system could be 
assembled with peristaltic pumps and heparinized blood, to serve as an in vitro simulation of 
analytical performance of the proposed design.  The effectiveness of transient NO as an anti-
thrombotic agent could be determined via use of the a pumping system connected to an in vivo 
animal, which would sample blood intermittently using a flow profile employed in the Edwards 
commercial system. 
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